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Summary
A!-amyloid peptide (A!), that plays a central role in the pathogenesis of
Alzheimer’s disease is derived by sequential proteolytic processing from the
amyloid precursor protein (APP) by ! - and ∀-secretase. APP is additionally
processed through a non-amyloidogenic pathway by #-secretase. Recent work
suggests that amyloidogenesis is highly dependent on the levels of cholesterol
within plasma membrane/early endosomes’ microdomains termed “rafts”. Indeed
APP cleaving machinery, required for A! generation has been shown to reside in
lipid rafts and the secretase activity on APP to depend on membrane cholesterol
levels. Counterintuitive to the localization of cleavage machinery, the substratum
protein APP localizes, at constitutive levels of expression, in membrane
microdomains enriched in phospholipids (PL), so-called non-raft domains. From
these two series of results it arises that not only cholesterol-rich rafts but also
cholesterol-poor/PL-rich non-rafts could be important modulators of AD
implicated APP processing.  In this work, I have addressed the question of how
changes in the lipidic content of non-raft domains, where APP concentrates,
affect proteolytic processing of this protein. As phosphatidylethanolamine (PE),
an important regulator of diverse cell processes, accounts for the majority of PL I
focused on the regulation of APP proteolyisis by this particular PL. For this
purpose I utilized Drosophila melanogaster and mammalian model systems.
Confirming previous work, APP was found in the non-raft domains of either insect
or mammalian cells, excluded from cholesterol/ergosterol/Flotilin that enrich in
rafts. The activity of ∀-secretase on APP that is the crucial step in A! generation
was assayed in Drosophila in vivo system using fly strains transgenic for human
APP-C-terminal fragment, fused to the GAL4-VP16 (GV) transcription factor.
Membrane PE levels in these ∀∃secretase reporter flies were depleted by
introducing the easPC80 mutation, that affects ethanolamine kinase (ETNK) an
enzyme involved in PE synthesis pathway. A strong downregulation of hAPP-Ct
processing by ∀-secretase, readout by GV triggered cell lethal GRIM and GFP
reporter genes expression was observed in low membrane PE flies compared to
the ∀-reporter flies with wild-type membrane PE levels.  The effect of PE on APP
proteolysis was additionally observed in mammalian HEK 293 cells stably
expressing hAPP. In these cells membrane PE levels were altered by the
treatment with RNAi directed against diverse PE synthesis enzymes including
ETNK. Membrane PE level decrease, caused by RNAi treatment was shown to
correlate with a downregulated ∀- and !-secretase processing of APP and
correspondingly an elevated #- secretase activity on APP. In the present study I
could show that besides cholesterol/raft microdomains, PL (in particular PE),
which are the major lipids in APP surrounding non-raft microdomains, appear to
be involved in the regulation of APP proteolysis.  From all the above I conclude
that APP cleavage efficiency is highly dependent on the levels of the lipidic
environment of non-raft domains, either because of affecting the degree of
accessibility of the responsible cleaving enzymes to APP or by affecting the
capacity of these enzymes to cleave the substratum. These are in my view
important venues for future investigation, opened by this work.
Zusammenfassung
Das Amyloid ! Peptid, das eine zentrale Rolle in der Pathogenese von Alzheimer Erkrankung (AD) spielt,
entsteht durch die sequentielle Prozessierung des Amyloid Precursor Protein (APP), durch die !- und ∀-
Sekretase. Zusätzlich kann APP in einem nicht-amyloidogenen Prozessierungsweg, durch die #-Sekretase
innerhalb der A!-Domäne proteolytisch gespalten werden.  Aktuelle Studien deuten darauf hin, dass die
Amyloidogenese in hohem Maße von dem Gehalt an Cholesterol in Mikrodomänen innerhalb der
Plasmamembran bzw. früher Endosomen abhängt. Diese cholesterolreiche Membrandomänen werden als
“Rafts” bezeichnet. Es ist gezeigt worden, dass die APP-Prozessierungsmaschinerie, welche für die
Amyloidogenese benötigt wird, in Rafts angereichert ist, und dass die Aktivität der Sekretasen von dem
Cholesterolgehalt in der Membran abhängt. Anders als seine Prozessierungmaschinerie, ist APP unter
physiologischen Bedingungen hauptsächlich in den Membrandomänen lokalisiert, die reich an
Phospholipiden (PL) sind und als “Non-Rafts” bezeichnet werden. Diese beiden Erkenntnisse führen zu der
Annahme, dass nicht nur cholesterolreiche, sondern auch die cholesteroarme/PL-reiche Membran-
Mikrodomänen eine entscheidende Rolle in der Regulierung der APP-Prozessierung und der Entstehung
des pathogenen A!-Peptids spielen.
In der vorliegenden Arbeit habe ich die Frage untersucht, ob und wie die Veränderungen in der
Lipidkomposition der Non-Raft-Domänen, wo APP konzentriert ist, dessen proteolytische Prozessierung
beeinflussen. Da Phosphatidylethanolamin (PE) zu den Hauptbestandteilen von Non-Raft-Mikrodomänen
zählt, wurde im Ramhen dieser Arbeit die Regulierung der APP-Prozessierung durch dieses spezielle PL
eingehend untersucht. Zu diesem Zweck wurden humane Zellen und Drosophila melanogaster als
experimentelle Systeme verwendet. In Übereinstimmung mit vorangegangenen Studien, wurde APP sowohl
in humanen Zellen als auch in Insektenzellen in den PL-reichen, Non-Raft-Domänen gefunden, in den keine
Raft-typischen Lipide (Cholesterol/Ergosterol) und Proteine (Flotillin) angereichert waren. Für die
Untersuchung der APP-Proteolyse durch die ∀-Sekretase, die den entscheidenden Schritt in der A!-Peptid
Entstehung darstellt, wurde das Drosophila in vivo System verwendet, genauer, transgene Reporterstämme,
die das humane APP-C-teminale Fragment exprimieren, das mit GAL4-VP16, einer Transaktivatordomäne,
fusioniert ist. GAL4-VP16 aktiviert die Transkription der Reportergene, deren Expression ein direkter
Indikator der ∀-Sekretase-Aktivität ist. Die Reportergene, die  ∀-Sekretase Aktivität indizieren, sind GRIM,
das die Apoptose in der Retina induziert und das Gen für das “Green Fluorescent Protein”, GFP. Der
Membrangehalt von PE in ∀-Sekretase-Reporterfliegen wurde durch die Kreuzung mit den easPC80-Mutanten
reduziert. Die easPC80-Mutation hat einen direkten Einfluss auf das Enzym Ethanolamin Kinase, das für die
PE-Synthese verantwortlich ist.
Vergleiche zwischen den ∀-Sekretase-Reporterfliegen, die einen Wild-typ PE-Membranlevel aufweisen und
den Reporterfliegen, mit dem niedrigen PE-Gehalt, zeigen in den letzteren eine starke Reduktion der ∀-
Sekretase-Aktivität, die durch das Ausmaß des retinalen Zelltodes und der GFP-Intensität indiziert wird.
Zusätzlich konnte ein Effekt von Membran-PE auf die APP-Proteolyse in den humanen HEK-Zellen, die das
humane APP exprimieren, festgestellt werden. Der Membrangehalt von PE wurde in diesen Zellen durch
den RNAi vermittelten knock-down der PE-Syntheseenzyme signifikant beeinflusst. Die Reduktion des
Membran-PE-Gehalts, durch die RNAi-Behandlung, zeigte eine klare Korrelation mit der starken Reduktion
von !- und ∀-Sekretase-Aktivitäten. Die Prozessierung von APP durch die #-Sekretase war stark erhöht.  In
der hier vorliegenden Studie konnte ich zeigen, dass neben Cholesterol und den Raft Mikrodomänen, den
PL (hierbei besonders PE), den meist vertretenen Lipid-Spezies, in den APP angereicherten Non-Rafts,
eine wichtige Rolle in seiner Proteolyse zukommt. Die oben genannten Gründe lassen deshalb den Schluss
zu, dass die APP-Prozessierung stark von der Beschaffenheit der Non-Raft-Domänen abhängig ist. Die
Rolle von Non-Rafts in der APP-Regulierung kann darauf beruhen, dass sie den Zugang der Sekretasen zu
dem Substrat modulieren oder direkt die Aktivität, der für die APP Prozessierung verantwortlichen Enzyme
beeinflussten. Diese Arbeit deutet darauf hin, dass die Non-Rafts ein wesentliches Stellglied für die APP-
Prozessierung sind und eröffnet damit neue Einblicke in die Regulationsmechanismen, den die APP-
Prozessierung und viel wichtiger, die Amyloidogenese, unterliegen.
1. Introduction
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1.1. Alzheimer’s Disease (AD)
Alzheimer’s disease, a progressive neurodegenerative disorder of the central
nervous system has been called “the disease of the century” because of its
staggering medical and social dimensions. On November 4th, 1906 Alois
Alzheimer first published his observations on the rapidly deteriorating mental
illness in a 51-year old woman called Auguste D, who had shown progressive
cognitive impairment, focal symptoms, hallucinations, delusions, and
psychosocial incompetence.  Characteristic clinical features of AD besides a wide
range of cognitive dysfunctions, of which the most common is the failure of
memory for recent events (Terry et al., 1994, Cummings 2000), are impairments
in attention, anxiety and emotional modulation (Ferretti et al., 2001, Foldi et al.,
2002). These conditions give a rise to a range of symptoms like depression,
panic, sleep disturbances, paranoia and delusion.  Alzheimer’s is the most
common form of dementia. Epidemiological studies show that AD affects 5-10%
of the population over 65, 20% after age of 40 and 43% after age of 90 years.
Most aggressive forms of AD, caused by autosomal dominant inheritance of
certain mutations, may have an onset younger than 30 years.
Histological analyses from the brains of demented patients versus non-demented
patients revealed the presence of bundles of fibrils within the neurons and
numerous focal lesions in the cerebral cortex. Most affected are the brain regions
responsible for cognitive function like, cerebral cortex, entorhinal cortex and
hippocampus. The brains of patients suffering AD are characterized by
extracellular accumulation of amyloid ! peptide (A!) and intracellular aggregates
of hyperphosphorylated tau, in so-called amyloid plaques and neurofibrilary
tangles respectively. Although not the exclusive pathological signs these are the
major hallmarks of AD.
Accumulation of aggregated A!, as the key pathological event driving
neurodegeneration in AD and Down’s syndrome was introduced by George
Glenner (Glenner and Wong, 1984).  Sequential cleavage of APP, by its cleaving
enzyme termed ∀-secretase generates 38-43-amino-acid A! peptides (Haas and
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De Strooper, 1999). The longer A! peptide (A!42), which represents 10% of all
A! species in the brain, seems to be the more amyloidogenic form of the peptide
since it is prone to aggregate. Hence A!42 peptides have an increased
propensity to accumulate as extracellular amyloid deposits in senile plaques and
cerebral blood vessels. Together with shorter fragments of the peptide in
amorphous form they constitute senile plaques in AD brains (Sellkoe, 1999).
Additionally to the 7-10nm-thick amyloid fibrils the mature plaques contain
degenerating axons and dendrites, and are surrounded and invaded by variable
numbers of microglia and reactive astrocytes.
Neurofibrilary tangles are intracellular aggregates of hyperphosphorylated tau
(Lee at al., 2001) consisting of 10nm-thick paired helical filaments. Aggregate
formation relies on elevated level of phosphorylated tau in the cells (Grundke-
Iqbal et al., 1986). Tau, a microtubule-associated protein is phosphorylated by
protein kinases, such as the neuron-specific cyclin dependent kinase 5 (cdk5).
This event precedes the organisation of highly phosphorylated tau protein in
paired helical fragments that causes the disruption of microtubules and ultimately
leads to cell death (Cruz et al., 2003, Noble et al., 2003).  Together with the tau
containing dystrophic neurons, neurofibrilary tangles are likely to be a
consequence of A! peptide accumulation (Hardy and Selkoe, 2002).
Although the pathology of AD is complex, amyloid cascade hypothesis, which
states that chronic imbalance between A! production and clearance leads to a
multistep cascade including gliosis, inflammatory changes, neuritic/synaptic
change, tangles and transmitter loss is considered to be the primary cause for
dementia in AD pathogenesis (Scheuner et al. 1996, Price et al., 1998, Hardy
and Selkoe, 2002, St. George-Hyslop and Petit, 2005, Tanzi and Bertam, 2005).
A! peptide is not produced as an independent protein but is instead generated by
proteolytic processing of a type I transmembrane protein, the amyloid precursor
protein (APP) (Kang et al., 1987, Tanzi et al., 1987). The role of APP in
Alzheimer’s disease became interesting as the mutations in the APP gene,
localized on chromosome 21 have been found in some rare forms of familial
early-onset AD (FAD) (Chartier-Harlin et al., 1991, Goate et al., 1991, Murell et
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al., 1991, Eckman et al., 1997).  Most of APP missense mutations alter APP
processing in a pathological manner by increasing either overall production of A!
peptide or generating highly fibrilogenic A! variants, like A!42. (Citron et al.,
1992, Cai et al., 1993, Haas et al., 1994, Suzuki et al., 1994, Price et al., 1998).
Interestingly AD related APP mutations were found within the region encoding A!
or immediately adjacent to !# and ∀-secretase cleavage sites (Hardy, 1996) that
strengthen the amyloid cascade hypothesis. In APP mutations linked FAD that
accounts for less than 5% of total AD cases, clinical and pathological symptoms
are nearly identical to that of the more frequent, late-onset sporadic AD. The
observations above strongly suggest that abnormal processing of APP plays an
important role not only in FAD but also in sporadic form of AD.
In addition to mutations in APP gene, FAD cases were linked to the mutations in
genes encoding presenilin-1 (PS1) and presenilin-2 (PS2), localized on
chromosome 14 and 1, respectively (Sherrington et al., 1995, Rogaev et al.,
1995, Levy-Lahad et al., 1995). Biochemically, FAD-associated mutations in PS
gene increase the relative concentration of the aggregation-prone A!42 (Sisodia,
2002, Iwatsubo, 2004). The mechanisms by which these mutations lead to a
selective increase of in the levels of A!42 species have not been fully resolved
yet.
There is also strong evidence that the ∃4 allele of apolipoprotein E (ApoE) is
associated with increased AD risk (Roses, 1998). ApoE4 plays a crucial role in
the metabolism and clearance of A! peptide. Like APP and PS genes, ApoE ∃4
allele impacts on A! production, deposition or clearance. This provides strong
genetic support to the role of amyloid cascade hypothesis in AD.
1.2. Amyloid Precursor Protein (APP)
Senile plagues in the brains of AD patients are deposits composed primarily of !-
amyloid insoluble peptides generated from the Amyloid Precursor Protein (APP).
APP is known to play a central role in the pathogenesis of AD but its
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physiological function is still not fully understood. Experiments in Drosophila
melanogaster indicate that APP might play an important role in the regulation of
cell adhesion and signalling (Beyreuther and Masters, 2001). Besides its role in
AD development A! domain appears to be crucial for correct APP functioning in
processes like axonal adhesion, neuritic outgrowth or regulation of synaptic
plasticity.
APP is a 110-120-kDa integral type I membrane glycoprotein that contains a
large amino terminal extracellular/cytosolic domain and a small intracellular
COOH-terminal domain (De Strooper and Annaert, 2000, Nunan and Small,
2000). This ubiquitously expressed protein is modified in the secretory pathway
by N-glycosylation and O-glycosylation in the endoplasmic reticulum (ER) and
the Golgi apparatus (Weideman et al., 1989, Sinha and Lieberburg, 1999).
Tyrosine sulfation and addition of phosphate in trans-Golgi network and at the
cell surface further increase the structural complexity of this protein. APP is
expressed as three alternatively spliced isoforms: APP695 (neuronal form),
APP770 and APP771 (peripheral and glial isoforms). APP770 and APP771
contain Kuniz-type protease inhibitor domain within the ectodomain.
Mammalian APP belongs to a protein family with two other members: the amyloid
precursor like protein 1 and 2 (APLP1 and APLP2). Two homologues have been
identified in invertebrates: the amyloid protein-like protein 1 (APL-1) in
Caenorhabditis elegans (Daigle, 1993) and the amyloid precursor protein-like
protein (APPL) in Drosophila melanogaster (Rosen, 1989). None of the
homologous members of the APP protein family exhibit sequence similarities
within the !-amyloid region that encodes the AD implicated A! peptide (Selkoe,
1996).
1.2.1. Proteolytic processing of APP
APP proteolytic processing is a membrane related event, which occurs by
sequential cleavage of APP by proteases termed %-, !- and ∀-secretase (Figure
1.1.). This process involves ectodomain shedding by either %- or by !-secretase
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and the retention of corresponding membrane-anchored C-terminal fragment,
%CTF (C83) and !C T F  (C99). ∀-secretase a multimeric protein complex
subsequently cleaves the % and !CTFs, in the middle of transmembrane domain
generating a 3-kda peptide (p3) and A! (4-kDa), respectively. Additionally to p3
or A! generation, ∀-cleavage releases the intracellular domain of APP (AICD)
after C83 or C99 processing. The APP processing pathway, in which %-secretase
precedes the ∀-secretase cleavage is so-called non-amyloidogenic pathway and
is the favoured pathway in non-neuronal tissue. The production of !-amyloid
peptide, relevant for AD pathogenesis is the product of sequential APP cleavage
by !- and ∀-secretase and it is the major APP prosessing pathway in neurons.
Both amyloidogenic and non-amyloidogenic pathways occur under physiological
conditions which indicates, that all products of APP proteolytic processing,
including A! are part of normal physiology (Haass et al., 1992, Seubert et al.,
1992).
A
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Figure 1.1. (A) Schematic diagram of the proteolytic processing of amyloid
precursor protein (APP). APP is a type I transmembrane protein that is processed by
%-, !- and ∀-secretase. APP processing by %-secretase is characterized by the release of
a large soluble ectodomain fragment (sAPP%) and the retention of a 10-kDa membrane
anchored fragment (C83). %-secretase cleaves APP within the A! domain (marked in
red) and prevents amyloidogenesis. Extracellular !-secretase mediated cleavage
produces a soluble APP-! fragment (sAPP!) that is shed in the extracellular space and a
membrane attached C-teminal fragment (C99). The membrane bound carboxy-terminal
fragments C99 and C83 are immediate substrates for ∀-secretase that cleaves in the
middle of transmembrane domain and generates 4kDa A! peptide and a small p3
peptide, respectively. Additionally ∀-secretase cut releases the APP intracellular domain
(AICD) that is known to be involved in nuclear signalling. Figure (B) depicts schematic
diagram of APP770 and APP695 isoforms and amino acid sequences of the
regions encompassing the A  sequence and the intracellular domain.  The APP770
isoform contains a serine protease inhibitor domain of the Kuniz type (KPI, starting form
the residue 289), while APP695 lacks this domain and is therefore shorter than APP770.
The amyloid-! sequence (labelled in red) is identical in both isoforms. Protease cleavage
sites in APP770 isoform (marked in green) are as follows: !-secretase cleaves after
residue 671, %-secretase cleaves after residue 687 and ∀-secretase cleaves after
residues 711 and 713, generating A!40 and A!42, respectively. APP695 isoform is
B
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cleaved by proteases at following cleavage sites (marked in blue): !-secretase cleaves
after residue residue 596, %-secretase cleaves after residue 612 and ∀-secretase
cleaves after residues 636 and 638, generating A!40 and A!42, respectively.
-secretase cleaves APP within A! domain between residues Lys16 and Leu17
(numbering according to the primary sequence of A! peptide), and therefore
precludes generation of intact A! peptide. As already mentioned above during
APP cleavage by %-secretase, a soluble ectodomain (sAPP%) is released into
extracellular space and a 10-kDa C-terminal fragment remains within the
membrane (C83) (Weidemann et al., 1989). SAPP% has been shown to have
neurotrophic properties (Small 1998), which could antagonize the neurotoxic
effect of A! peptide. Cleavage of C83 by ∀-secretase releases a short peptide
(p3), containing the C-terminal part of A! peptide. The biological significance and
the role of p3 in amyloidogenesis remain obscure. Several zinc metalloproteases
including TACE (tumor necrosis factor-% converting enzyme; or ADAM17), ADAM
(a disintegrin and metalloprotease) 9, ADAM10 and MDC9 and an aspartyl
protease BACE2 can cleave APP at the %-secretase site (Allinson, 2003).
The APP cleavage by %-secretase may occur in the trans-Golgi compartment
(Sinha and Lieberburg, 1999), at the cell surface or within calveolae (Lammich et
al., 1999, Kosik, 1999). At the membrane level %-secretase that is involved in
non-amyloidogenic APP processing pathway has been shown to act in the non-
raft membrane microdomains (Kojro et al., 2001, Ehehalt et al., 2003). ADAMs
are not only found in vertebrates but also in Caenorhabditis elegans, Drosophila
melanogaster and Xenopus. It has been shown that Drosophila %-secretase
processes human APP in a similar manner like in mammalian cells, generating a
CTF corresponding in size to mammalian %CTF (C83)  (Fossgreen et al., 1998,
Loever et al., 2003). One of the best candidates responsible for this %-secretase
activity in Drosophila is the protease Kuzbanian (Kuz). Kuz belongs to the ADAM
family, members of which contain contain both a disintegrin and metalloprotease
domain.
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-secretase is involved in amyloidogenic processing of APP and is the first
prerequisite for generation of A! peptide. This enzyme cleaves APP at the Asp+1
residue of A! sequence, and generates two products: a secreted soluble
fragment (sAPP!) and the membrane bound APP C-terminal fragment,
composed of 99 amino acids (!CTF or C99). Subsequently ∀-secretase cleaves
C99 producing a spectrum of intact !-amyloid peptide plus the APP intracellular
domain (AICD). A !-site APP cleaving enzyme, BACE (beta-site APP-cleaving-
enzyme; also called Asp-2 and memapsin-2) has been identified by several
groups by genetic screening, and by direct enzyme purification and sequenzing
(Hussain et al., 1999, Vassar et al., 1999, Yan et al., 1999). BACE is a
transmembrane protein characterized by a large extracellular domain, containing
two aspartate residues involved in !-secretase activity (Hussain et al., 1999) and
it is a member of pepsin family of aspartyl proteases. Affinity of BACE1, which is
the major neuronal !-secretase toward APP is relatively low. Interestingly,
Swedish type of missense mutation in APP gene, which is known to enhance A!
generation, promotes cleavage of APP by BACE (Vassar et al., 1999).
!-secretase has maximal activity at acidic pH (Haass et al., 1993 and 1995,
Knops et al., 1995). Indeed cell biological studies indicate that BACE colocalizes
with endosomes and trans-Golgi (Koo and Squazzo, 1994, Haass et al., 1995,
Walter et al., 2001) and that its activity is highest in these subcellular
compartments that provide acidic environment. Another important aspect
regarding !-secretase activity is its localization and activity on APP within the
lipid rafts (Ridell et al., 2001, Ehehalt et al. 2003, Cordy et al., 2003, Abad-
Rodriguez et al., 2004). Homologues for BACE in invertebrates, e.g. in
Drosophila melanogaster have not been reported.
-secretase cleavage of APP is the major step in the generation of A! peptide.
This intramembrane protease cleaves APP fragments generated by %- and !-
secretase within the membrane and produces secreted fragments consisting of
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nontoxic p3 and toxic !-amyloid peptide, respectively and the intracellular domain
of APP, AICD. As described above ∀-cleavage of APP C-terminal fragments
generates a spectrum of amyloidogenic species and the exact position of ∀
cleavage site is critical for AD pathogenesis. Besides  APP ∀-secretase cleaves a
number of substrates like E-cadherin, N-cadherin, ErbB-4, CD44, p75
nurothropin receptor, and most importantly the protein Notch (Struhl and
Greenwald, 1999, 2001, Ye et al., 1999, Thinakaran and Parent, 2004), which is
involved in cell fate decision in the embryo and in the adult. The process in which
∀-secretase cleaves APP and Notch within the plasma membrane is an example
of a much more general process known as regulated intra-membrane proteolysis
(RIP). RIP is a highly conserved from bacteria to humans and it is involved in a
numerous cellular regulatory events, including lipid homeostasis (Brown et al.,
2000).
∀-secretase is a membrane-bound enzyme complex comprised of at least four
components including Presenilin 1 and 2  (PS1, PS2), Nicastrin (Nct), anterior
pharynx-defective phenotype (APH-1) and Presenilin enhancer (PEN-2) (Figure
1.2.). Several studies indicate that ∀-secretase endoproteolyzes its substrates
through a GX’GDX’’-type catalytic site (X’ is variable, and X’’ is preferably a
hydrophobic amino acid) residing within the 6th and the 7th transmembrane
domain (TMD6, TMD7) of PS (Steiner et al., 2000). Hence Presenilins appear to
be a central catalytic component of ∀-secretase. Preseniln (PS) is an aspartyl
protease whose membrane topology is characterized by 7- to 8-membrane
spanning domains (Figure1.2.), with the sixth and seventh domain containing
aspartate residues (Asp257 and Asp385), responsible for the catalytic activity.
PS is synthesized as an immature, inactive holoprotein, which is subsequently
endoproteolyzed by an unknown activity to generate N- (NTF, ~-30kDa) and C-
terminal (CTF, ~20-kDa) fragments, which are thought to associate to form the
active enzyme (Thinakaran et al., 1996, Rattovitski et al., 1997, Levitan et al.,
2001). Nicastrin (Nct), a glycosylated type I transmembrane protein (~130-kDa)
conatins a large N-terminal extracellular and a short C-terminal intracellular
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domain (Figure 1.2.). Nct is an additional putative component of ∀-secretase
complex, which exists, similar to PS as an immature and a mature protein
(Edbauer et al., 2002, Leem et al., 2002). The mature isoform of Nct is
associated with active ∀-complex. N-terminal part of Nicastrin, that contains
several conserved cysteines and a conserved functionally important DYIGS
motif, associates with PS and COOH-terminal fragments of APP and Notch (Yu
et al., 2000, Chen et al., 2001, Capell et al., 2003) and it has been proposed to
be required for PS-mediated cleavage at the cell surface in Drosophila (Chung
and Struhl, 2001) and mammalian cells (Kaether et al., 2002).  But PS and Nic
alone do not suffice for the formation of an active ∀-secretase complex. Indeed
two other members of ∀-secretase complex were identified through genetic
screens in Caenorhabditis elegans, APH-1 and PEN-2. APH-1 is a 30-kDa
multipass membrane protein containing seven transmembrane segments.
Together with Nct APH-1 works as a scaffold and facilitates the assembly and
trafficking of ∀-secretase (La Voie et al., 2003, Niimura et al., 2005). PEN-2 a 12-
kDa membrane protein with two transmembrane segments is incorporated into
the PS-Nct-APH-1 complex through direct binding to TMD4 of PS. It causes PS
endoproteolyisis, which avails its proteolytic activity to other substrates (Takasugi
et al., 2003, Watanabe et al., 2005, Kim et al., 2005).
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Figure 1.2. Schematic depiction of the -secretase complex and its putative
components: Presenilin (PS), Nicastrin (Nct), APH-1 and PEN-2. ∀-secretase is a
membrane bound protein complex consisting of at least four different integral membrane
proteins: PS, Nic, APH-1 and PEN-2 (left panel). PS contains eight transmembrane
domains, NH2- and COOH-terminal cytoplasmic domains, and a large intracellular
hydrophilic loop domain (right panel). Catalytic aspartate residues in PS transmembrane
domains 6 and 7 indicate that PS may comprise the active site of ∀-secretase.
Endoproteolytic processing of immature PS generates a PS heterodimer, which is
thought to be component of the mature, active ∀-secretase. The red box represents the
endoproteolytic cleavage site. Nct is a type I transembrane protein, with an extracellular
domain that contains several conserved cysteines and a functionally important DYIGS
motif, and a relatively small intracellular domain. Together with APH-1 and PEN-2, that
contain seven and two transmembrane segments, respectively, Nct is required for the
maturation, trafficking and the activity of the ∀-secretase complex.
At the subcellular level, ∀-secretase activity have been shown to reside in multiple
compartments including the ER, late-Golgi/TGN, endosomes and the plasma
membrane (Xu et al., 1997, Cook et al., 1997, Greenfield et al., 1999, Takahashi
et al., 2002, Kaether et al., 2002).  Only 6% of total ∀-activity had been detected
at the cell-surface (Chyung et al., 2005). The majority of the active components
of ∀-complex are present in ER/Golgi intermediate compartments, Golgi
apparatus, the trans Golgi network (TGN), and late endosomes (Vetrivel et al.,
2004). Recent biological evidence suggests that ∀-secretase components
assemble into the proteolytically active complex in the Golgi/TGN compartments
(Baulac et al., 2003). Similar to BACE1, active components of ∀-secretase
activity, namely PS1 derived fragments, mature Nct, APH-1 and PEN-2 associate
with lipid raft microdomains (Vetrivel et al., 2004), although interestingly ∀-
secretase activity seem to be independent of the presence of cholesterol (Wada
et al., 2003). Presenilins, Nicastrin, APH-1 and PEN-2 enable the highly
conserved ∀-secretase proteolytic activity in mammalian, insect or yeast cells
(Takasugi et al., 2003, Kimberly et al., 2003, Hayashi et al., 2004).
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A novel APP cleavage taking place a few residues C-terminal to the ∀-site has
been recently reported (Gu et al., 2001, Yu et al., 2001, Sastre et al., 2001,
Weidemann et al., 2002). Remarkably, it shares similarities with S3 Notch
cleavage site. The -cleavage site of APP resides at Leu-49 distal to the ∀-
secretase site, and is thought to be involved in the regulation of APP cleavage
generating APP intracellular domain, that similar to its Notch counterpart appears
to mediate important physiological functions. Evin and colleagues suggest that ∃-
CTF may be derived from ∀CTF by a rapid action of a second protease in the
cytosol (Weidemann et al., 2002). Alternatively ∃-cleavage may represent an
intermediate step in A! formation that would precede ∀-cleavage at 40- or 42-
position (Weidemann et al., 2002). This observation indicates that ∀- and ∃-
cleavages on APP could be seen as either deleterious (∀-site) or beneficial (∃-
site) events, and that modulation of ∃-cleavage may contribute to the regulation of
the neurotoxic amyloid-! peptide generation implicated in AD pathogenesis. This
cellular mechanism is still poorly understood and further studies are required to
clarify the function of this cleavage.
1.2.2. Modulators of APP proteolytic processing
Generation of amyloid-! peptide by APP proteolytic processing plays a central
role in the pathophysiology of AD (Beyreuther and Masters, 1997) and is
therefore an interesting target from pharmaceutical point of view. Particularly
modulation of APP by !- and ∀-secretase, enzymes involved in amyloidogenic
processing of APP may stop or prevent neurodegenerative processes
characteristic for AD. But also %-secretase cleavage of APP is an issue in
amyloidogenesis, as %-secretase cleaves APP within A! domain preventing the
deposition of intact A! peptide. Moreover sAPP%, a large soluble domain,
produced by %-processing of APP has neuroprotective and memory-enhancing
effects (Barger and Harmon, 1997, Meziane et al., 1998).
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As already described APP and its proteolytic machinery consisting of %-, !# and
∀-secretase reside at the membrane. It seems likely that APP and the proteases
being membrane proteins respond to their lipid environment in a way that could
eventually affect their activity. Indeed strong evidence indicates a functional
relationship between AD and amyloidogenesis with lipid metabolism (Simons et
al., 2001, Kalvodova et al., 2005, Vetrivel and Thinakaran, 2006). Although
alterations in several lipid species including phospholipids, ceramides and
sphingolipids have been reported to correlate with AD pathogenesis and AD
related events (Prasad et al., 1997, Han, 2005, Kalvodova et al., 2005),
cholesterol and cholesterol rich membrane domains, rafts have received the most
attention during the past few years (Puglielli et al., 2003, Wolozin, 2004, Vetrivel
and Thinakaran, 2006).
The reasons for the interest in this lipid are several fold. There are epidemiologic
data that show a direct relationship between cholesterol and AD.  For instance
high cholesterol levels are shown to be an important risk factor in AD
pathogenesis (Hofman et al., 1997). Further, Kivipelto et al. (2001) reported that
elevated cholesterol levels during mid-life increase the risk of developing the
disease. Additionally cholesterol metabolism is genetically linked to AD through
ApoE ∃4 allele (Sing and Davignon, 1985), which is the major genetic factor for
developing the disease (Strittmatter et al., 1993, Corder et al., 1993). Clinical
studies indicating that there is a decreased prevalence of AD associated with the
treatment of cholesterol synthesis inhibitors (statins) (Jick et al., 2000, Wolozin et
al., 2000, Austen et al., 2002) are supported by studies in animal models that
have revealed a significant decrease of A! generation in animals fed with statins
(Fassbender et al., 2001) and on the other hand an accumulation of A! due to
the cholesterol rich diet (Sparks et al., 1996, Refolo et al., 2000). The
epidemiological data find support in cell biological studies. Thus, cholesterol
reduction at the cellular level by inhibition of its de novo synthesis with statins
alone or in combination with cholesterol extracting agent, methyl-!-cyclodextrin
results in a strong decrease of A! production (Simons et al., 1998, Fassbender et
al., 2001, Ehehalt et al., 2003). Amyoidogenic processing of APP by ∀- and !-
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secretase is affected by cholesterol depletion as indicated by a marked reduction
of !CTF and A! peptide generation (Simons et al., 1998, Ehehalt et al., 2003).
The non-amyloidogenic APP processing pathway seems to be stimulated by
cholesterol loss, since reduction of cholesterol levels causes an increase in the
production of APP ectodomain generated by %-secretase (Kojro et al., 2001).
Taken together the results described above suggest that cholesterol depletion
favours the non-amyloidogenic pathway, while inhibiting the AD implicated
amyloidogenic APP processing by !- and ∀-secretase.
Contrary to the above view it has been shown that mild reduction of cholesterol
leads to an increased amyloidogenesis in neurons indicating the importance and
requirement of cholesterol for APP proteolysis (Rodriguez et al., 2004). These
results are supported by observations showing that rodents treated with the statin
most permeable to the blood brain barrier show an increased A! generation and
senile plaque deposition (Park et al., 2003). The discrepancy between these last
results with the above may rely on several factors (see Kaether and Haass, 2004,
Ledesma and Dotti 2006) and future work is needed to settle this controversy.
Nevertheless what is clear from all these two series of results is that cholesterol
can play a key role in the regulation of APP processing, possibly by restricting the
access of proteases to their substrate. (Kaether and Haass, 2004, Kalvodova et
al., 2005). Hence an altered A! peptide generation in cholesterol low membranes
is likely to rely on an aberrant access of !- and ∀-secrtetase to their substrate.  A
crucial cell membrane structure that may act as a link between cholesterol and
APP processing are cholesterol/sphingolipid enriched lateral assemblies within
the membrane so-called lipid rafts.
Biological membranes are complex structures composed of lipids, that have
multiple and distinct roles in cellular function (Roberts et al., 2002, Hardie et al.,
2003). Although membranes contain thousands of individual lipid molecular
species three lipid species are the main components of cellular membranes:
sterols, sphingolipids and phosphoglycerolipids (phospholipids) (Figure 1.3.).
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Sterols are based on a rigid four-ring structure, with cholesterol being the
principle form found in vertebrate. Sphingolipids contain C18 alcohol sphingosine
or dihydrosphingosine, their homologs or their derivatives (ceramide) associated
with either a phopshocholine headgroup (sphigomyelin) or one of a range of
carbohydrate structures (glycosphingolipids). In sphingolipids both acyl chains
are often saturated. Phosphoglycerolipids comprise one of several headgroups
(phosphocholine, phosphoethanolamine, phosphoserine and phosphoinositol)
attached via glycerol to two acyl chains, one of which is usually unsaturated.
Sphingolipids are longer and more saturated than phospholipids, and would
therefore be predicted to have a higher melting temperature than phospholipids.
Figure 1.3. Major membrane lipid species in mammals and Drosophila. (A) Sterol
structure is based on a rigid four-ring structure. Cholesterol is the most abundant sterol
in the membranes of the mammalian cells. Flies cannot synthesize sterols and require
therefore a dietary source that is mainly yeast with ergosterol being the major sterol
cholesterol ergosterol
sphingomyelin
PECer
PEPC
A
B
C
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species. (B) The structural unit of mammalian and Drosophila sphingolipids is C18
alcohol sphingosine or dihydrosphingosine, their homologues or their derivatives
(ceramide). Sphingomyelin, the major sphingolipid in mammalian membranes is
composed of ceramide and phosphocholine. Instead in Drosophila membranes
phosphoethanolamine ceramide (PECer) accounts for the majority of membrane
sphingolipids and it contains ceramide and phosphoethanolamine. Typically, amide-
linked fatty acids (R’) present in sphingolipids are saturated or monounsaturated. (C)
Most phosphoglycerolipids (phospholipids) contain a saturated fatty acid (R’) on C-1 and
an unsaturated fatty acid (R”) on C-2 of the glycerol backbone.  The most commonly
added alcohols (serine, ethanolamine and choline) also contain nitrogen that may be
positively charged, whereas, glycerol and inositol do not. The major phospholipid
species in mammals besides phosphatidylcholine (PC) is phosphatidylethanolamine
(PE) that is present in Drosophila membranes with 55% of total phospholipids.
At the subcellular levels sterols and sphingolipids are not distributed
homogeneously  (Ikonen, Vainio and Lusa, 2005).  Other than in the plasma
membrane, the membranes of early endosomes and the endosomal recycling
compartment, which are enriched in sterols and sphingolipids, these lipids are
present at low levels in endoplasmic reticulum (ER) and cis Golgi membranes.
Also within membranes lipid distribution is not homogenous. Instead membrane
lipids have high affinities towards each other and tend to form lateral assemblies
within the membrane.  One such assembly termed rafts are known to be an
important regulator of polarized intracellular sorting and signal transduction
(Simons and Ikonen, 1997, Brown and London, 1997, Simons and Toomre,
2000). Moreover a large body of evidence suggests that these specialized
membrane domains are related to AD pathogenesis (see above, and Simons et
al., 1998, Simons et al., 2001, Fassbender et al., 2001, Ehehalt et al., 2003,
Abad-Rodriguez et al., 2004, Vetrivel and Thinakaran, 2006). Lipid raft formation
is based on the tendency of cholesterol to organize the membrane bilayer in
cholesterol-rich liquid ordered and cholesterol-poor liquid disordered domains
(Sankaram and Thompson, 1991). Pure phospholipid bilayers can exist in two
states a “gel” state or “liquid” state. The presence of rigid sterol in the
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physiologically relevant liquid phase causes phospholipid acyl chains to become
closely packed or compacted, and the bilayer to be thickened.  This high
cholesterol bilayer in which phospholipid acyl chains cannot readily deform is
termed liquid-ordered phase, in contrast to liquid-disordered state “without”
cholesterol. Formation of liquid-ordered phase is enhanced by preferential
interaction of cholesterol with sphingolipids and the fact that sphingolipids have a
higher melting temperature than phospholipids. The “separation” of
cholesterol/sphingolipid-rich liquid-ordered membrane domains from the
phospholipid-rich phase that constitutes the rest of the membrane leads to raft
formation.   Raft assembly takes place in the Golgi, and they are predominantly
located at the plasma membrane. Biochemically lipid rafts are defined as
detergent resistant microdomains (DRM) that resist extraction with a non-ionic
detergent, like Triton X-100 (Yu et al., 1973, Brown and Rose, 1992, London and
Brown, 2000, Edidin, 2003).
Raft microdomains have also been found in the membranes of Drosophila
melanogaster (Rietveld et al., 1999). Drosophila membranes are similar to those
in mammals regarding their lipid composition. Like in mammalian membranes
major lipidic components in Drosophila membranes are sterols, sphingolipids and
phosphoglycerolpids. In contrast to mammalian membranes in which cholesterol
accounts for the majority of membrane sterols, in Drosophila membranes
ergosterol represents the major sterol species (Figure 1.3. A). Flies incorporate
dietary (yeast) sterols into their membranes, as they have only a part of sterol
synthesis machinery and are therefore disabled to synthesize sterols. The only
phosphosphingolipid in mammals, sphingomyelin is not present in Drosophila
membranes. Instead Drosophila membranes contain phosphoethanolamine
ceramide (PECer) (Figure 1.3. B). Despite differences in chemical structure
between mammalian and Drosophila lipids, the properties of sterols,
sphingolipids and phospholpids that allow raft formation have been preserved.
Both ergosterol and PECer are enriched in insoluble membranes (Rietveld et al.,
1999).
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As mentioned above, strong evidence indicates that rafts may be the principal
membrane platforms where amyloidogenic processing of APP takes place. The
importance of raft microdomains for APP processing, particularly in
amyloidogenic pathway is strongly supported by the enrichment of entire A!
generating machinery within the lipid raft microdomains (Li et al., 2000, Wahrle et
al., 2002, Ehehalt et al., 2003, Rodriguez et al., 2004, Vetrivel et al., 2004). A
further evidence for the role of rafts in amyloidogenesis is the concentration of
monomeric and oligomeric A! in DRM in the brains of a mouse model for AD
(Lee et al., 1998, Kawarabayashi et al., 2004). Opposite to ! and ∀-secretase
activity in rafts, %-secretase involved in non-amyloidogenic APP processing takes
place outside rafts (Ehehalt et al., 2003).
On the other hand, it is also strong the evidence that amyloidogenic processing
of APP, is mostly taking place within phospholipid rich or non-rafts membrane
domains (Rodriguez et al., 2004). This would be consistent with the view of
Ehehalt et al. (2003), who suggest the existence of APP in two pools, in raft and
non-raft domains, rendering possible that both, lipid rafts and non-raft domains
are important regulators of APP cleavage. Although large body of evidence
support the cholesterol/raft role in APP processing event, very little is known
about the role of APP surrounding phospholipidslipids and non-rafts in its
proteolytic processing. The colocalization of APP with these membrane domains
strongly suggests the phospholipid role as APP cleavage modulators and the
analysis of their role in APP proteolysis may shed important light on
amyloidogenesis.
Although phospholipids are major components of cell membranes, the role of
phospholipids in the physiology of the cell is just beginning to be understood.
Phospholipids play multiple roles in cells being important components in cell
signalling, by providing the matrix for the assembly and function of a wide variety
of catalytic processes and therefore actively influencing the functional properties
of membrane-associated processes (Berridge and Irvine 1984, Nishizuka 1986,
Fadok et al., 1992, 2000, Vance and Vance, 1996, Dowhan et al., 1997,
Alessenko and Burlakova, 2002). One of those membrane related events
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implicated in AD  (BACE-activity) has been shown recently by Simons and
colleagues to be regulated by phospholpids (Kalvodova et al., 2005). Similar to
the sterols phospholipids show altered levels in the brains of Alzheimer’s patient.
In particular PE membrane levels are affected in AD brains while PC and
phosphatidylinositol (PI) do not show significant changes in AD brains compared
to control (Wells et al., 1995, Prasad et al., 1997). Among all phospholipids PE
appears to be the most interesting candidate for modulation of APP proteolytic
processing. Besides PC, PE is the most abundant phospholipid in eukaryotic
cells, and it constitutes 20-40% and 55% of the total phopholipids in mammalian
and in Drosophila cell membranes, respectively (Figure 1.3. C). PE is involved in
a variety of cell processes. It has been shown to be required for membrane
protein activity, it serves as “chaperone” and, along with other “non-bilayer” lipids,
PE seems to be important for maintaining the physical state of the bilayer
(Bogdanov et al, 1996, van der Brink-van der Laan, 2004). Recently Drosophila
PE has been shown to regulate SREBP (sterol regulatory element-binding
protein) processing, an event that is regulated by sterols in mammalian cells
(Dobrosotskaya et al., 2002). Unlike PC and PS, which form flat bilayers, PE can
form non-bilayer structures under physiological conditions. These structures,
observed in vitro, may provide discontinuity in the membrane bilayer for several
important biological functions like vesicle-mediated protein trafficking, lateral
movement of macromolecules within bilayer, stabilization of specific membrane
protein complexes (Dowhan et al., 1997).
PE is synthesized via two main pathways: CDP-ethanolamine pathway (Kennedy
et al., 1957) and phosphatidylserine (PS) dexarboxylation pathway (Merrill, 1997,
Dickson and Lester, 1999, Hannun and Luberto 2001; Figure 1.4.). While in
insects the CDP-ethanolamine pathway is known to be the major source of PE
(Downer et al., 1985), in mammalian cells the utilization of that pathway is tissue
dependent. Kennedy pathway is the primary pathway in mammalian tissues such
as the brain and the hart (Butler and Morell, 1983, McMaster et al., 1993, Arthur
and Page, 1991).  In liver and kidney tissue PE is mainly synthesized by PS-
dexarboxylation.
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Figure 1.4. The major pathways for biosynthesis of phosphatidylethanolamine de
novo in eukaryotic cells. Scheme is based on data from mammalian and yeast
systems. PE is mainly synthesized through CDP-ethanolamine pathway and
phosphatidylserine decarboxylation pathway. The first step in CDP-ethanolamine
pathway which is the major pathway in Drosophila and in mammalian neuronal tissue is
phosphorylation of ethanolamine by ethanolamine kinase (ETNK), followed by reaction
of the product with cytidine triphosphate (CTP) to form cytidine diphosphoethanolamine
(CDP-ethanolamine). CDP-ethanolamine phosphotransferase, catalyses the reaction of
the last compound with diacylglycerol to form phosphatidylethanolamine (PE).
Additionaly to CDP-ethanolamine pathway, PE is synthesized through dexarboxylation of
phosphatidylserine by phosphatidylserine decarboxylase.
Phosphoethanolamine
Citidylyltransferase (PECT)
Ethanolamine Kinase
CDP-Ethanoalmine
Phosophotransferase (CEPT)
Phosphatidylserine
Decarboxylase
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1.3. Goals of my PhD thesis
The processing of APP by its cleaving enzymes plays a crucial role in
A D  pathogeneis, and is therefore an important pharmacological target.
Membrane lipids in particular cholesterol/sphingolipid rich membrane
microdomains are important candidates for regulation of APP proteolysis. The
localization of APP processing enzymes responsible for amyloidogenic APP
cleavage supports the regulatory role of cholesterol and rafts in amyloidogenesis.
But the finding that APP localization in neurons and non-neuronal cells is largely
restricted to the phospholipid rich liquid disordered phase strongly indicates the
importance of these membrane domains for APP processing and
amyloidogenesis. In addition, the crucial role that PE plays in variety of
membrane occurring enzymatic activities strengthen the hypothesis that PE may
be an important factor in the regulation of APP proteolysis. Present study has
been performed in order to understand whether PE plays a modulatory role in the
regulation of APP proteolytic processing by %-, !- and ∀-secretase, as indicated
by several factors described above.
The modulation of the APP processing by PE will be analysed by utilizing
Drosophila in vivo and in vitro model system and mammalian in vitro model
system. In the first part of my thesis I will focus on the analysis of PE role on %-,
!- and ∀-secretase activity by using mammalian HEK 293 cells, overexpressing
wild-type APP.
The second part, in which the experiments will be performed in a more
sophisticated Drosophila in vivo system is aimed at addressing the PE
modulatory role on the crucial step of A! generation, namely APP processing by
∀-secretase. Presenilin dependant ∀-secretase activity, that is highly conserved in
mammals and Drosophila melanogaster will be analysed in the flies transgenic
for APP-C-terminal fragment, initiating just downstream of the !-secretase
cleaving site that is known to be processed In Drosophila in a similar manner like
in mammalian cells, generating A! peptide and APP intracellular domain (AICD).
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Transgenic fly lines utilized for that purpose GMR-APP-GAL4, UAS-GRIM and
APP-GAL4-VP16, UAS-cd8-GFP act as a sensitive and specific reporter of the
endogenous, physiological levels of ∀-secretase. PE levels in transgenic flies will
be modulated by introducing the easPC80 mutation with a known biochemical
effect in phospholipid metabolism, particularly in PE synthesis that allows the
investigation of specific consequences of defects in phospholipids, or rather PE
metabolism. The properties of Drosophila sterols, sphingolipids and
phosoholipids that allow the formation of liquid ordered/raft phase and liquid
disordeded/non-raft phase provide optimal conditions to analyse the role of
membrane microdomains in APP proteolysis. Additionally I will analyse the
influence of membrane PE on ∀-secretase activity in Drosophila embryonic
Schneider-2 (S2) cells.
2. Materials and Methods
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2.1. Cell biology
2.1.1. HEK 293-hAPP cells
2.1.1.1. Culturing HEK 293-hAPP cells
Human epithelial kidney 293 cells (HEK 293), stably transfected with wild-type
APP695 (the cells were kindly provided by Dr. Christian Haass) were grown in
Doelbeco’s Minimal Essential Medium (DMEM-Gibco) containing 10% fetal
bovine serum (FBS, Sigma), 2 mM L-glutamine (Sigma), 100u/ml Penicillin
Streptomycin solution (Sigma), 200 µg/ml G418 sulfate antibiotic Liquid
(Invitrogen) at 370C and 5% CO2.
HEK 293 cells stably transfected with the APP cDNA containing the Swedish
mutation were generous gift from Dr. De Strooper. The cells were maintained in
DMEM with 10% FBS, 100u/ml Penicillin Streptomycin solution and 250 µg/ml
G418 at 370C and 5% CO2.
2.1.1.2. RNAi transfection of HEK 293-hAPP cells
On day before transfection, HEK 293-hAPP cells were harvested by
trypsinization and 6 x 105 cells were plated in 4 ml of growth medium without
antibiotics per 6 cm dish.  At the time of transfection cells were 50% confluent.
Prior to transfection cells were washed once in Opti-MEM I Reduced Serum
Medium (Invitrogen) and subsequently switched to 3 ml of the same medium of
per dish. 1000 pmol RNAi were diluted in 500 µl of Opti-MEM I Reduced Serum
Medium for each sample. 10 µl Lipofectamine 2000 (Invitrogen) were diluted in
500 µl of Opti-MEM I Reduced Serum Medium, and after 5 minutes incubation at
room temperature combined with the diluted RNAi. RNAi/Lipofectamine mixture
was incubated for 15 minutes at room temperature and subsequently added to
the cells. RNAi transfected cells were incubated at 370C and 5% CO2. Cells were
assayed 48 hours after RNAi transfection.
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2.1.2. Drosophila Schneider-2 (S2) cells
2.1.2.1. Culturing S2 cells
S2 cells grow at 250C without CO2 as a loose, semi-adherent monolayer. The
cells were purchased from Invitrogen and grown in Schneider’s Insect Medium
(Sigma) containing 10% heat-inactivated FBS (Sigma) and 100u/ml Penicillin
Streptomycin soluton.
2.1.2.2. DNA transfection of S2 cells
Schneider cells were transient transfected with 15 µg of SC100 construct that
contains hC99 fragment (Maryama et al., 1994; Figure 2.1.), with Calcium
Phosphate Transfection Kit (Invitrogen). At day 1, 3 x 106 cells were seeded in
3ml of S2 complete growth medium in each well of a 6-well format and incubated
over night at 250C without CO2. At day 2, 3-4 hours before transfection cells were
switched to the fresh complete growth medium. Transfection mixture was
prepared according to the manufacturer’s protocol and added to the cells after 30
minutes of incubation at room temperature. 18 hours post-transfection calcium
phosphate solution was removed, and the cells washed twice with 1 x Phosphate
Buffered Saline (PBS). Subsequently S2 cells were resuspended in 3 ml fresh
complete growth medium and replated to the same vessel.  Cells were incubated
at 250C without CO2 and analysed for the gene of interest 48 or 72 hours after
transfection.
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Figure 2.1. Amino acid sequence encoding for APP695-C-terminal fragment (hC99;
M596-N695) that is contained in the SC100 construct. The fragment initiates just C-
terminal to the !-secretase cleavage site (M596) and encompasses the A! domain and
the intracellular domain. The cleavage sites of  ∀-, !- and #-secretase are indicated by
arrowheads.  A! domain is shown in red.
2.1.2.3. RNAi transfection of S2 cells
S2 cells were set up for the RNAi transfection by placing 2 x 106 cells in 2 ml of
antibiotic free S2 growth medium into each well of 6-well culture dish. After 24
hours cells were resuspended in 1.5 ml of serum and antibiotic free IPL-41 Insect
Medium (Invitrogen). Subsequently 50 µg/ml of RNAi were added to the cells. Six
hours later, 1.5 ml of IPL-41 Insect Medium containing 20% of FBS were added
to each well, and the cells were incubated over night at 250C without CO2. S2
cells were re-suspended, re-treated with RNAi and re-plated each 24 hours and
analyzed 48 hours after the first RNAi treatment.
2.1.3. Determination of cell viability
Cell viability was analysed by measuring apoptosis and necrosis level. Apoptosis
was scored by using Apoptosis Detection System, Fluorescin (Promega). This
assay is based on DNA labelling by catalytically incorporating of fluorescin –12-
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dUTP(a) at 3’-OH DNA ends using the enzyme Terminal Deoxynucleotidyl
Transferase (TdT), which forms a polymeric tail using the principle of the TUNEL
(TdT-mediated dUTP Nick-End labelling) assay. The cells were prepared for the
assay as described in manufacturer’s protocol and analyzed by fluorescence
microscopy.  Necrosis was measured by Trypan blue uptake. Trypan blue
(Sigma) stock solution of 8% was prepared in 0.9% NaCl, diluted 1:9 in HBSS
and subsequently mixed 1:1 with the cell suspension. Cell viability is indicated by
the fraction of dye-excluding cells.
2.2. Biochemistry
2.2.1. Preparation of cell lysates for protein and lipid analysis
HEK 293-hAPP cells were washed once in 1ml of cold washing buffer (1 x PBS,
CLAP (chymostatin, leupeptin, antipain and pepstatin A, each of the final
concentration of 25µg/ml, Sigma)), mechanistically removed from the culture
dishes in 2 ml of lysis buffer (1 x PBS, CLAP, 0.2% Triton X-100 (Merck)),
incubated for 15 minutes on ice and homogenized by 10 passages through a 27-
gauge syringe.
The medium of S2 cells was collected and the cells that grow in suspension were
centrifuged to pellet for 5 minutes by 1000 x g at 40C (Microcentrifuge 5415R,
Eppendorf). Cell pellet was washed in 1 x PBS/CLAP, resuspended in lysis buffer
containing 1 x PBS, CLAP and 0.2% (v/v) Triton X-100, and subsequently
incubated for 15 minutes on ice in order to avoid the protein degradation. After 15
minutes on ice cells were homogenized by 10 passages through a 27-gauge
syringe. HEK 293-hAPP and S2 cell lysates were centrifuged for 10 minutes by
400 x g at 40C to pellet the nuclei and to remove cell debris; the supernatants
were considered as total extracts. Protein concentration was assayed in
Spectrophotometer Genesys 10 UV-VIS (Thermo Spectronic), using Bradford
reagent (Bio-Rad Laboratories).
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2.2.2. DRM separation using Triton X-100
HEK 293-hAPP or S2 cells were extracted in a buffer containing 25 mM MES (2
(N-morpholino)-ethanesulfonic acid) pH 7.0, 5 mM DTT, 2 mM EDTA pH 8.0, 1%
Triton X-100, CLAP. After 1 hour of incubation in lysis buffer at 40C under
rotation, cells were centrifuged 10 minutes by 400 x g at 40C in order to pellet the
nuclei and to remove cell debris. Membrane pellets were obtained by cell extracts
(containing 100 µg of total protein) centrifugation for 1hour at 40C at 100, 000 x g
i n  Ultracentrifuge Optima Max E (MLA-103 rotor; Beckman). Extracted
membrane pellets were resuspended in 1 ml of solution buffer (10 mM MES,
2mM EDTA, 1mM DTT), brought to 40% OptiPrepTM solution (AXIS-SHIELD PoC
AS) and overlaid with 30% and 5% OptiPrepTM solution in solution buffer. The
subsequent OptiPrepTM step gradient centrifugation was performed in
Ultracentrifuge Le80 (SW40 rotor; Beckman ) at 120, 000 x g for 18 hours at 40C.
After centrifugation 1 ml of each of following gradient fractions were collected: 5
% fraction, the interphase between 5% and 30% fraction, 30% fraction and 40%
fraction. Subsequently each fraction was centrifuged by 100, 000 x g for 1 hour at
40C to extract the membranes that were utilized for the analysis of membrane
lipids and membrane proteins. The interphase between the fractions 5% and
30% was identified as the DRM fraction by the presence of the DRM markers.
2.2.3. Western blot analysis
For analysis of membrane proteins total cell extracts were centrifuged for 1 hour
at 100, 000 x g at 40C to pellet the membrane fraction. Crude membranes were
resuspended in 0.2% (w/v) Sodium Dodecyl Sulfate (SDS) and after protein
measurement by Bradford protein assay the proteins were denatured for 5
minutes in 1 x SDS sample buffer (22mM Tris-HCl pH 6.8, 0.8% (w/v) SDS, 4%
glycerol, 1.6% (w/v) !-Mecaptoethanol, Bromphenolblue) at 950C. Samples for
the analysis of membrane bound proteins isolated form the membranes
fractionated by OptiPrep gradient were prepared as described above. Cytosolic
Materials and Methods
28
proteins were directly diluted in 1 x SDS sample buffer and denatured for 5
minutes at 950C. Denatured proteins were subjected either to the Tris-glycine-
acrylamide SDS-PAGE or to the urea version of the Bicine/bis-Tris/Tris/sulfate
SDS-PAGE (Wiltfang et al., 1991) and separated by electrophoresis.   Tris-
glycine-acrylamide gels were run at constant voltage of 100 volts, and the urea
version of the Bicine/bis-Tris/Tris/sulfate SDS-PAGE gels were run at room
temperature at the constant current of 12 mA/gel, using the Mini-PROTEAN II
electrophoresis cell (Bio-Rad Laboratories).
After gel electrophoresis, proteins were transferred to a 0.45 !m nitrocellulose
transfer membrane (Schleicher & Schuell BioScience) using a constant voltage of
100 volts for 1 hour, with transfer buffer (48 mM Tris, 38 mM glycine, 0.037% (vv)
SDS, 20% (v/v) methanol) in a Mini Trans-Blot electrophoretic transfer cell (Bio-
Rad Laboratories). Subsequently membrane was incubated in blocking solution
(5% (w/v) non-fat powder milk dissolved 1 x in TBS-T buffer (25 mM Tris/HCl pH
7.4, 150 mM NaCl, 4 mM KCl, 0.1% (v/v) Tween-20) at 40C overnight. Primary
and secondary antibodies were diluted in blocking solution containing 1% (w/v)
powder milk to the appropriate concentrations (Table 1). Species specific
peroxidase-conjugated antibodies and the enhanced chemiluminescence (ECL)
(Amersham Biosciences) were used followed by the exposure to x-ray films
(BioMax Light Film for Chemiluminescent Imaging, Kodak Co). Quantification
was done by densitometry of autoradiograms using Image J software.
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Primary antibody Descripton Clonality Company
Dilutions
for WB
ANTI-AMYLOID
PRECURSOR
PROTEIN (APP)
C-Terminal
C-Terminus (95-100
kDa) of APP695,
APP770 and APP771
polyclonal Sigma 1:1000
Monoclonal Anti-
Human ! Amyloid
[1-17] Clone 6E10
Residues 1-17 of the
human !-amyloid
peptide
monoclonal Sigma 1:500
A.v. Peptide
Antibody
Central and C-
Terminal portion of
Aequorea victoria
green fluorescent
protein
monoclonal
BD
Biosciences
1:400
Anti-Flotillin-1 Flotillin-1 ~48k-Da monoclonal
BD
Biosciences
1:500
Anti-∀-Tubulin ∀-Tubulin ~60-k-Da monoclonal Calbiochem 1:1000
E18
 A! amino terminal-
selective
monoclonal nanoTools 1:300
WO2 A! residues 5-8 monoclonal Abeta Gmbh 1:1000
Table 1 Collection of primary and secondary antibodies that were used for Western blot
(WB) assay.
2.2.4. Immunoprecipitation of A  peptides and their electrophoretic
separation.
For analysis of A ! peptide, medium from the S2 cells was collected and
immunoprecipitated. Magnetic sheep anti-mouse immunoglobulin G (IgG)
Secondary antibodies Company Dilution
Horse radish
peroxidase antibody
(sheep anti mouse)
Amersham 1:5000
Horse radish
peroxidaseantibody
(donkey anti rabbit)
Amersham 1:5000
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Dynabeads M-280 (Dynal) were preactivated by overnight incubation at 40C with
monoclonal A! amino terminal-selective antibody, 1E8 (nanoTools) according to
the manufacturer’s protocol. Eight hundred µl of medium were added to 200 µl
fivefold concentrated RIPA detergent buffer (2.5% (v/v) Nonidet-P40, 1.25% (w/v)
sodium deoxycholate, 0.25% (v/v) SDS, 750 mM NaCl, 250 mM HEPES, one
tablet of Protease Inhibitor Cocktail Complete per 2ml of 5 x RIPA, pH 7.4), 25 µl
preactivated magnetic Dynabeads (1 ml 1E8 mouse antibody/1.68 x 107 beads)
and 300 µl H2O. Samples were than incubated overnight at 4
0C under rotation,
following washing of the beads four times with PBS/0.1% bovine serum albumin,
and once with 10 mM Tris/HCl, pH 7.4. For A!-SDS-PAGE-Immunoblot, bound
A! peptides were eluted by heating the samples to 950C for 5 minutes with 25µl
sample buffer. For separation of A! peptides the urea version of the Bicine/bis-
Tris/Tris/sulfate SDS-PAGE was used. Gels were run at room temperature for 2
hours at the constant current of 12 mA/gel, using the Mini-PROTEAN II
electrophoresis cell (Bio-Rad Laboratories). A! peptides were transferred for 30
minutes at 1 mA/cm2 and room temperature under semidry Western conditions
onto Immobilon-P PVDF membranes (Millipore) (according to Witlfang et al.,
1997) and incubated in the blocking solution containing 2.5% (w/v) non-fat
powder milk 1 hour at room temperature. The membranes were than
immunostained overnight with monoclonal amino terminal-selective antibody,
1E8 (nanoTools) at 40C. After the washing step the membranes were incubated
for 1 hour at room temperature with an anti-mouse biotinylated antibody (Vector
Laboratories), washed, and horseradish peroxidase-coupled streptavidin
(Amersham Biosciences) was added for 1 hour. After the final washing step,
chemiluminescence was visualized with ECLPlus solution (Amersham
Pharmacia) according to the protocol of the manufacturer, using the CCD camera
system (FluorSMaxMultiImager, Bio-Rad).
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2.2.5. Enzyme-linked immunosorbent assay (ELISA)
ELISA assay, utilized for A! 42 detection in the extracellular medium from the
HEK 293-SweAPP695 cells, was performed using the highly sensitive microtiter
plate Enzyme-Immunoassay for the quantitative detection of human Amyloid !
42, hAmyloid ! 42 ELISA (HS) (the GENETICS company). This assay is based
on the formation of an antibody-Amyloid-antibody complex, which is indirectly
linked to an enzyme that catalyses the conversion of the substrate in a coloured
product which colour intensity is measured by means of photometry. The
measured extinction correlates directly with the concentration of hAß42 within the
sample. The analysis was done according to the manufacturer’s protocol.
2.2.6. Analysis of soluble APP  in the medium of HEK 293-hAPP cells
Soluble APP∀, which is released into the medium after APP cleavage by ∀-
secretase was analysed in the medium of HEK 293-hAPP cells. For sAPP∀
analysis 50 µl medium were diluted in 50µl 2 x sample buffer and heated to 950C
for 5 minutes. The samples were subjected to 10% SDS-PAGE and run at the
room temperature at the constant voltage of 200 volts for 40 minutes, using the
Mini-PROTEAN II electrophoresis cell (Bio-Rad Laboratories). After
electrophoresis a Western blotting was performed using semidry conditions and
Immobilon-P PVDF membranes. Subsequently the membranes were incubated
for 1 hour at room temperature in the blocking solution containing 2.5% (w/v)
non-fat powder followed by the overnight antibody incubation with monoclonal
amino terminal-selective antibody, 1E8 (nanoTools) at 40C. After washing with
PBS/Tween, incubation at room temperature with an anti-mouse biotinylated
antibody (Linaris) and the subsequent incubation with horseradish peroxidase-
coupled streptavidin (GE Healthcare) chemiluminescence was visualized with
ECLPlus solution (Amersham Pharmacia) using the CCD camera system
(FluorSMaxMultiImager, Bio-Rad).
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2.2.7. Lipid extraction and analysis by Thin Layer Chromatographie (TLC)
Cell membranes obtained after 100, 000 x g centrifugation were resuspended in
800 µl of 0.9% (w/v) sodium chloride (NaCl) containing 37% (v/v) chloridc acid
(HCl) and homogenized with a 22-gauge syringe. Membrane lipids were than
extracted according to Bligh and Dyer (1959). After addition of 2 ml methanol and
1 ml chloroform to 800 µl suspension containing cell membranes, 1 ml chloroform
and 1 ml of 0.9% (w/v) NaCl containing 37% (v/v) HCl were added to the sample,
mixed well, incubated 10 minutes on ice to allow the phase separation and
centrifuged at 1000 rpm for 5 minutes at 40C (Allegra 25R-High-Performing-
Centrifuge, TA-14-50 fixed angle rotor; Beckman). The upper phase was
discarded and 2 ml methanol plus 1.8 ml of 0.9% (w/v) NaCl/37% (v/v) HCl were
added to the interphase and the lower phase and kept on ice for minutes.
Subsequently the samples were centrifuged at 1000 rpm for 5 minutes at 40C
and the lower phase was collected and dried in a rotational vacuum concentrator
(Centrifuge RVC 2-25; Christ) to obtain lipid pellets. Lipid pellets were
resuspended in 1:1 methanol/chloroform mixture, applied to the silica gel 60
HPTLC plates (Merck) and separated first in the hydrophilic running solvent,
composed of chloroform:acetone:acetic acid:methanol:H2O (50:20:10:10:5) and
subsequently in the hydrophobic running solvent containing hexane:ethyl acetate
(5:2).  The HPTLC plates were than dried at room temperature and stained with
7% (v/v) sulfuric acid (H2SO4) in methanol. Standards for cholesterol, ergosterol
and sphingomyeline (Sigma), and PC, PE, and PECeramide (Matreya, Inc.) were
used to identify these lipid species. For the lipid quantification the scanned TLCs
were analysed in conditions of non-saturated signal by Image J software.
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2.3. Molecular Biology
2.3.1. Rapid Small Scale Isolation of Drosophila genomic DNA (Walter,
1991)
To prepare genomic DNA from S2 cells, about 20 millions of cells were collected
and centrifuged to the pellet at 1000 x g for 5 minutes at 40C. Cell pellet was
resuspended in solution A (0.1 M Tris/HCl pH 9.0, 0.1 M EDTA, 1% (v/v) SDS,
1% DEPC, homogenized with a 27-gauge needle and incubated for 30 minutes at
700C. After incubation 14 µl of 8M KAc per 1 ml of solution A were added and
incubated for another 30 minutes on ice. Subsequently the solution was
centrifuged for 15 minutes at room temperature, the 1/2 volume of isopropanol
was added to the supernatant and centrifuged again for 5 minutes at room
temperature. The supernatant was discarded, the pellet was washed with 70%
(v/v) ethanol, centrifuged, dried in a speed vacuum concentrator and finally
dissolved in 100 µl of pH 7.4 TE buffer (10 mM Tris/HCl pH 7.4, 1 mM EDTA pH
8.0)
2.3.2.  RNA interference (RNAi) synthesis
2.3.2.1. RNAi synthesis for the treatment of S2 cells
2.3.2.1.1. Preparation of PCR template for RNAi synthesis directed against
Drosophila phosphoethanolamine citidylyltransferase gene
Two primers, forward and reverse, designed to target Drosoph i l a
phosphoethanolamine citidylyltransferase, PECT (CG5547-gene number refers
to the Berkeley Drosophila Genome Project designation) messenger RNA have
following sequences:
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Forward primer 5’-3’
GAATTAATACGACTCACTATAGGGAGAGTGGGCATTCACACCGACGAGGA
GATCACC
Reverse primer 5’-3’
GAATTAATACGACTCACTATAGGGAGACTTCAGTGACACAGTAGGGAGCTC
CG
Each primer contains a sequence encoding the T7 RNA polymerase binding site
(bold), followed by the appropriate coding sequence. The T7 RNA polymerase
binding site sequence is required for the subsequent RNAi synthesis. The
oligonucleotides were synhtetized by Invitrogen.
The DNA template for RNAi synthesis was synthesized and amplified by PCR
reaction (performed in Thermal Cycler PTC 100; MJ research), set-up as follows:
20 µg of Drosophila genomic DNA
150 ng of both forward and reverse PECT primers
Taq polymerase buffer (Promega) to final concentration of 1x
dNTPs  to final concentration of 0.2 mM each (Promega)
5 units Taq polymerase (Promega)
1.5 mM Mg2+ (Promega)
H2O to a final volume of 100 µl
PCR program
Step 1) 940C 4   minutes
Step 2) 940C 15 seconds
Step 3) 580C 30 seconds
Step 4) 720C 2 minutes
Step 5) back to the step 2) 30x
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Step 6) 720C 7 minutes
The completed PCR reaction was purified using High Pure PCR Product
Purification Kit (Roche) according to kit-supplied protocol and examined on a 1%
agarose gel.
2.3.2.1.2. Transcription reaction assembly
The Ambion  MEGAscriptTM T7 kit was used to synthesize RNAi from templates
obtained as described under 2.3.2.1.1.
The reaction was set-up as follows:
3 µl H20 containing 0.1% (v/v) Diethyl pyrocarbonate (DEPC; Sigma)
2 µl 10 x reaction buffer
2 µl of each ATP, CTP, GTP, UTP mixes
5 µl DNA template
2 µl enzyme mix,
and incubated for 8 hours at 370C.
After 8 hours, DNase was added for 15 minutes at 370C. After 15 minutes
reaction was stopped with 15 µl of stop solution (5 M ammonium acetate, 100
mM EDTA). The RNAi was extracted by phenol/chloroform extraction method
and precipitated with isopropanol overnight at -200C. After precipitation the RNAi
was washed with 70% (v/v) ethanol and concentrated in a speed vacuum
concentrator. The RNAi was analysed on a 1% agarose gel (Agarose LE;
Euroclones) and the concentration was determined by measuring the absorbance
at 260 nm (A260) in a spectrophotometer using quartz cuvettes. An absorbance of
1 unit a 260 nm corresponds to 40 µg of RNA per ml (A260 =1=40 µg).
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The RNAi directed against Drosophila easily shocked (eas) gene was designed
using Dharmacon siDESIGN Center. The eas RNAi and predesigned control
RNAi directed against rat CYP7A1 were purchased from Dharmacon RNA
TECHNOLOGIES:
easily shocked sense sequence 5’-3’:        AAACGGACCUACUGAUAGAUU
easily shocked antisense sequence 5’-3’:      UCUAUCAGUAGGUCCGUUUUU
CYP7A1 sense sequence 5’-3’:        UAAACAACCUUGACAACUUUU
CYP7A1 antisense sequence 5’-3’:    5’-PAAGUUGUCAAGGUUGUUUAUU
2.3.2.2. Synthesis of RNAi oligonucleotides directed against human
phosphoethanolamine citidylyltransferase, (PECT), CDP-ethanolamine
phosphotransferase (CEPT) and ethanolamine kinase 1 and 2 (ETNK1 and
ETNK2) genes utilized for the transfection of HEK 293 cells
The RNAi oligonucleotides for the treatment of HEK 293 cells were designed with
Dharmacon siDESIGN Center:
ETNK1 sense sequence 5’-3’:                  CGAUCGAGAUGAGGAAGUA
ETNK1 antisense sequence 5’-3’:         UACUUCCUCAUCUGCAUCG
ETNK2 sense sequence 5’-3’:        UCAGGUUAAUCGCCUUAGA
ETNK2 antisense sequence 5’-3’:         UCUAAGGCGAUUAACCUGA
PECT sense sequence 5’-3’:        CCAACAGGUUGGAGUAUGA
PECT antisense sequence 5’-3’:        UCAUACUCCAACCUGUUGG
CEPT sense sequence 5’-3’:                    UCAUUGGACUGUCAAUAAA
CEPT antisense sequence 5’-3’:         UUUAUUGACAGUCCAAUGA
The RNAi oligonucleotides were purchased form MWG Biotech AG.
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2.3.3. Propagation and isolation of the SC100 construct
For the transformation with SC100 construct chemocompetent E.coli cells (DH5∀
strain, Gibco) were thaw on ice. 10 ng SC100 DNA were added to the bacteria
cells, incubated for 20 minutes on ice, 2 minutes at 370C and again on ice for 2
minutes. Subsequently 400µl of Luria-Bertani broth medium (LB) (0.5% (w/v)
NaCl, 1% (w/v) Trypton, 0.5% (w/v) Yeast-Extract, 2M Tris/HCl pH 7.5) were
added and incubated for 1 hour at 370C. After 1 hour of incubation the cells were
plated onto the LB-Agar plates containing 100µg/ml Ampicilin and incubated
overnight at 370C.  A single bacteria colony was selected for inoculation of 200
ml of LB-medium culture containing 100µg/ml Ampicilin. After an incubation of 18
hours at 370C at 180 rpm the bacterial culture was harvested by centrifugation at
4000 x g for 10 minutes at 40C (Allegra 25R-High-Performing-Centrifuge, TA-10-
250 fixed angle rotor; Beckman). The DNA was purified using QIAGEN-EndoFree
Plasmid Maxi Kit according to the manufacture’s protocol. Extracted DNA was
examined on 1% agarose gel after control digestion with AgeI and KpnI
restriction enzymes (New England Biolabs) in order to confirm the propagation of
the desired construct.
2.4. Flies
The flies were raised on standard fly food at 180C or 250C with 60-70% relative
humidity.
2.4.1 Drosophila transgenic lines and mutants utilized in this work
Oregon R strain was utilized as wild-type control.
GMR-APP-GAL4, UAS-GRIM and GMR-GAL4, UAS-G/RPR transgenic flies
were kindly provided by Dr. Ming Guo (Departement of Neurology, Brain
Research Institute, The David Geffen School of Medicine, University of
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California). GMR-APP-GAL4, UAS-GRIM transgenic system contains a type I
chimeric protein containing human APP770 C-terminal fragment (APP770-Ct;
initiating from the residue M671) that is appended to GAL4 on its C-terminal end
(Figure 2.2.). APP770-Ct-GAL4 is specifically expressed in the eye under the
control of the eye-specific GMR promoter. The reporter flies carry additionally to
APP-GAL4, a #-secretase reporter output construct, UAS-GRIM, that consists of
a GAL4-responsive transcriptional cassette driving the expression of the
Drosophila cell death activator GRIM. In GMR-GAL4, UAS-G/RPR flies GAL4 is
expressed specifically in the eye under eye-specific GMR promoter but this
transgenic strain do not contain APP770-Ct fragment. The expression of GRIM
cell lethal gene is as above triggered through the activation of UAS by GAL4.
APP-GAL4-VP16, UAS-cd8-GFP transgenic strain was established in the
laboratory of Dr. Dotti, by recombining the APP-GAL4-VP16 fusion flies
(generous gift from Dr. Gary Struhl, Department of Genetics and Development,
Howard Hughes Medical Institute, Columbia University) with UAS-cd8-GFP
transgenic flies. This transgenic system contains APP695-C-terminal fragment
(APP695-Ct) that initiates immediately downstream of !-cleavage site (residue
M596). APP695-Ct is fused to the transcription factor GAL4-VP16 (GV) just
downstream of the transmembrane domain (Figure 2.2.). After its intramembrane
proteolysis APP C-terminal end the nucleus together with GV (APP-C-t-GV) and
induces the expression of a nuclear UAS-cd8-GFP reporter gene.
APP770 and APP 695 isoforms do not differ in their C-terminal domains so that
chimeric proteins in both transgenic strains GMR-APP-GAL4, UAS-GRIM and
APP-GAL4-VP16, UAS-cd8-GFP have identical amino acid sequence (see
figures 2.2. and 1.1. B).
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Figure 2.2. Amino acid sequence of the extracellular and transmembrane domain
of chimeric protein form APP reporter flies. GMR-APP-GAL4, UAS-GRIM flies
contain the APP770 C-terminal fragment; C-terminus of APP695 is contained in APP-
GAL4-VP16 (GV), UAS-cd8-GFP transgenic flies. Both APP770 and APP695 C-terminal
fragments are identical and encompass the extracellular domain that initiate directly after
!-secretase cleavage site and the transmembrane domain. GAL4-VP16 transcription
factor that is inserted just downstream of APP-Ct transmembrane domain is linked to the
stop transfer signal through the last amino acids of APP-Ct (KK). Arrows indicate
putative secretase cleavage sites of ∀-, !- and #-secretase. Amino acids inside the A!
domain is labelled in red.
EasPC80f mutant flies were a kind gift of Dr. Mark Tanouye (Department of
Molecular and Cell Biology Division of Neurobiology, Department of
Environmental Science, Policy, and Management, University of California).
Ethanolamine kinase gene, termed easily shocked (eas) is localized on the X
chromosome. The mutation in easPC80 allele relies on a 2bp deletion at nucleotide
position 1004-1005, which causes frame shift in the open reading frame leading
to a stop codon in-frame at nucleotide position 1078. The peptide has only a
portion of the conserved sequence and lacks completely the highly conserved
kinase domain. EasPC80 mutant gene is marked by a recessive expressed marker
termed forked (f) that is localized on the X chromosome. Forked that causes
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short bristles with split or bent ends was utilized to identify homozygous easPC80
mutants.
2.4.2. Analysis of adult eye phenotype
Progeny transgenic for GMR-APP-GAL4, UAS-GRIM and homozygous for
easPC80f mutation were obtained by crossing homozygous female easPC80f
mutants with the male transgenic GMR-APP-GAL4, UAS-GRIM flies.
Homozygous easPC80f progeny with following phenotype: easPC80f/Y; GMR-C99-
GAL4, UAS-GRIM/+ and easPC80f/easPC80f; GMR-C99-GAL4, UAS-GRIM/+ were
selected against forked marker and together with the control flies assayed for the
adult eye roughness and the eye size.  The eye size and the size of roughened
eye surface are indicators for the level of retinal cell death that directly correlates
with the expression of the cell lethal GRIM gene. Adult eye roughness was
calculated as the percentage of the total eye surface. The eye size of adult
progeny was measured in comparison to the wild-type flies and the transgenic
flies without easPC80 mutation. About 150 eyes/genotype were analysed by
scoring images obtained by high-resolution light microscopy (Stereo microscope
SZX9; Olympus).  All measurements were performed in one-day-old adult flies.
Progeny homozygous for easPC80f mutation, obtained by crossing male control
transgenic flies GMR-GAL4, UAS-G/RPR with the female easPC80f mutants   have
a genotype as follows: easPC80f/easPC80f; GMR-GAL4, UAS-G/RPR/+. These
flies were selected against the marker forked and analysed for retinal cell death
as described above.
2.4.3. Analysis of GFP expression
Homozygous easPC80f  mutants transgenic for APP-GAL4-VP16, UAS-cd8-GFP
(phenotype: easPC80f/Y; APP-GAL4-VP16, UAS-cd8-GFP/+) were obtained by
crossing the female easPC80 homozygous with the male APP-GAL4-VP16, UAS-
cd8-GFP transgenic flies. GFP expression in the progeny and control flies was
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analysed by measuring the fluorescence intensity using Image J software or by
Western blotting. In order to induce GFP expression one-day-old adult flies were
heat shocked for 1 hour at 370C, placed at 250C to allow GFP expression and
subsequently analysed by fluorescence intensity and Western blot assay. High-
resolution light microscopy images were utilized for the analysis of fluorescence
activity. For the Western blot analysis of the GFP protein expression 10 fly bodies
were homogenized in lysis buffer containing 10 mM Tris/HCl [pH 7.4], 150 mM
NaCl, 5 mM EDTA, 5 mM EGTA, 10% glycerol, 50 mM NaF, 1 mM NaVOF, 5
mM DTT, 4 M Urea, and protease inhibitors (CLAP), resolved by 15% Tris-
glycine-acrylamide SDS-PAGE and analyzed as described under 2.2.3. using
Anti-GFP-peptide antibody (BD Biosciences).
2.4.4. Membrane lipid analysis in flies
For the membrane lipid analysis 10 fly bodies (GFP reporter flies) or 20 fly heads
(GRIM reported flies) were homogenized in lysis buffer (10 mM Tris/HCl [pH 7.4],
150 mM NaCl, 5 mM EDTA, 5 mM EGTA, 10% glycerol, 50 mM NaF, 1 mM
NaVOF, 5 mM DTT, 4 M Urea, and protease inhibitors (CLAP)). After
homogenization, the fly debris were centrifuged for 10 minutes by 18, 000 x g at
40C, followed by the protein measurement in supernatant and cell membrane
centrifugation by 100, 000 x g at 40C for 1 hour, using the same amount of total
protein as starting material for all samples. Subsequently the lipids were
extracted and analysed as described under 2.2.6.
3. Results
Results
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3.1. Role of phosphatidyethanolamine (PE) in APP proteolytic
processing in HEK 293 cells
3.1.1. Phosphatidylethanolamine distribution in the cell membranes of HEK
293 cells
In mammalian cells phosphatidylethanolamine (PE) represents one of the major
membrane phospholipids. In addition to roles in normal cellular function, the
possible involvement of PE in pathological situations, more precisely in AD, arose
as consequence of the observation of altered PE levels in the brains of
Alzheimer’s patients (Wells et al., 1995, Prasad et al., 1997). While this is per se
not an enough argument to strongly propose that PE are involved in the
occurrence of AD (different from the changes being a consequence of it), this
postulate can be also supported by the fact that, as mentioned in the chapter
1.2.2., PE is involved in membrane occurring enzymatic activities. This acquires
further relevance if one accepts the view that one of the causes of AD is an
increased amyloidogenic cleavage of APP, a membrane occurring event. As
already described in the introduction, one of the by-products of APP cleavage is
the neurotoxic A! peptide, whose accumulation in the brain mesenchime is
thought to be the cause of this disease. Therefore, we propose that changes in
the PE content, can induce abnormal APP cleavage, leading to a perturbed
production of A!.  In further support of this view, APP was shown to colocalize
with phospholipid rich membrane domains (Ehehalt et al., 2003, Abad-Rodriguez
et al., 2004).
To gain insight into the above proposal I started by determining the distribution of
PE in the membrane, measuring its levels in raft and non-raft domains. In order
to determine PE distribution we utilized HEK 293 cells, the membranes of which
were subjected to density gradient centrifugation. Gradient centrifugation allows
the separation of cholesterol/sphingolipid rich phase from the phospholipid rich
phase that constitutes the rest of the membrane.
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The most widely used criterion for the separation of cholestrol/sphingolipid rich
domains or rafts from non-rafts, is their insolubility in the nonionic detergent
Triton X-100 at 40C. After membrane solubilization in the nonionic detergent, raft
associated lipids and proteins remain insoluble and can be floated to low density
by OptiPrep gradient centrifugation.
To analyse the distribution of PE in the membranes of HEK 293 cells, cell
membrane pellets were isolated by 100,000 x g centrifugation and subsequently
solubilized at 40C in a 1% Triton X-100 containing buffer. For the separation of
detergent resistant or raft lipid microdomains (DRM) from the detergent soluble,
non-raft microdomains, cell membrane pellets were loaded on an OptiPrep
gradient and centrifuged at 120,000 x g for 18 hours at 40C. To be certain that I
had succeeded in the raft and non-raft isolation, the proteins from each gradient
fraction were concentrated, re-suspended in sample buffer and subjected to 12%
SDS-PAGE following by Western blotting for the detection of the raft associated
protein, Flotilin-1. The interphase between 5% and 30% was identified as raft
fraction, since the raft marker Flotilin-1 was significantly enriched in this gradient
phase (Figure 3.1.1.). Further proof that rafts do become enriched in the 5% and
30% fractions of this type of gradient, comes from the observation that this is the
fraction with most cholesterol (Figure 3.1.2).
Figure 3.1.1. Flotilin-1 associates specifically with detergent insoluble membrane
microdomains (DRM) in HEK 293 cells.  Cellular membranes solubilized with 1%
Triton X-100, were collected by flotation through the OptiPrep gradient. Subsequently,
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the membranes of each gradient fraction were isolated by 100,000 x g centrifugation and
subjected to 12% SDS-PAGE. Western blot analysis revealed an association of 41% of
total Flotilin-1 with insoluble membrane fraction (DRM). As shown in the graph, 57% and
2% of total Flotilin-1 are detected in 40% and 30% fraction, respectively. The 5% fraction
is not represented in the graph, since no Flotilin-1 was detected in this fraction.
After confirming the efficacy of the method for raft and non-raft fractions
purification, PE distribution in these domains was analyzed by TLC. As before,
cell membrane pellets were isolated by 100,000 x g centrifugation, followed by
gradient centrifugation and membrane lipids extraction procedures (see Materials
and Methods).
Figure 3.1.2. PE is equally distributed in the membranes of HEK 293 cells.  After
separation of membrane microdomains by OptiPrep gradient, membrane lipid extracts of
DRM and non-DRM fractions were analysed by TLC. Lipid analysis showed that PE is
equally distributed along the gradient, with about 25% of its total amount in each fraction.
75% of membrane PE is localized in non-raft domains, which encompass 5%, 30% and
40% fractions. DRM contain only 25% of PE. In contrast, the portion of total cholesterol
was approximately 50% in the intephase between 5% and 30% fractions corresponding
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to detergent insoluble microdomains (DRM). 5%, 30% and 40% gradient fractions
contain 14%, 16% and 20% of total membrane cholesterol, respectively. The percentage
of total PE and cholesterol in respective gradient fraction are depicted in the graph.
In the membranes of HEK 293 cells PE is equally distributed in raft and non-raft
lipid microdomains, while cholesterol is, consistent to the Flotilin-1 localization,
clearly enriched in the interphase between 5% and 30% gradient fractions (DRM)
(Figure. 3.1.2.). PE ratio in non-rafts averages 0.75 versus only 0.25 in rafts,
while the half (0.5) of total membrane cholesterol enriches in the raft fraction.
3.1.2. Localization of Amyloid Precursor Protein (APP) in the membranes of
HEK 293 hAPP cells
Several studies have clearly indicated that membrane lipids are involved in
pathogenesis of AD (Kuo et al. 1998, Jick et al. 2000, Wolozin et al.2000,
Kivipelto et al.2001, Austen et al., 2002, Simons et al., 2002). In particular,
cholesterol and cholesterol rich membrane microdomains seem to play an
important role in APP proteolytic processing and generation of neurotoxic A!
peptide (Simons et al., 1998, Simons et al., 2001, Fassbender et al., 2001,
Ehehalt et al., 2003, Abad-Rodriguez et al., 2004).
However, it was unequivocally shown, in both neuronal and non neuronal cells,
that APP is, at endogenous levels, mostly, if not exclusively, present in the
phospholipid rich/cholesterol poor membrane microdomains (Abad-Rodriguez et
al., 2004), suggesting, without excluding the involvement of rafts, that non-raft
domains may participate in the regulation of APP cleavage. Yet, before directly
addressing this issue, I tested whether or not APP partitioning was, as in
neuronal cells, restricted to non-raft domains in the HEK cells where I identified
PE partitioning.
To determine APP membrane partitioning/localization, HEK 293 cells stably
transfected with human APP were solubilized, and cell membrane pellets were
isolated by centrifugation of cell extracts at 100,000 x g for 1 hour at 40C. The
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separation of raft from non-raft domains was performed as described, through
density centrifugation in OptiPrep gradient. Then, the cell membrane pellets from
each gradient fraction were isolated by 100,000 x g centrifugation, subjected to
10% SDS-PAGE and blotted with an APP C-terminal specific antibody (ANTI-
APP, C-terminal, Sigma), to detect APP and identify its distribution along the
gradient. Western blot analysis showed that in HEK 293 hAPP cells, APP is,
consistently what described in neuronal cells, largely restricted to the non-raft,
phospholipid rich domains (Figure 3.1.3.). 23% and 77% of total APP are present
in the 30% and 40% fraction, respectively.  Furthermore, APP was not detectable
neither in DRM, the raft associated Flotilin-1 and cholesterol/sphingolipids
enriched fraction, nor in   the 5% fraction
Figure 3.1.3. In the membranes of HEK 293 cells APP accumulates in the heavy,
phospholipid rich fraction. After separation of DRM from non-DRM fractions by
OptiPrep gradient, cell membranes of each fraction were isolated and subjected to 10%
SDS-PAGE, to determine the distribution of APP along the gradient.  Staining with ANTI-
APP, C-terminal antibody reveals an accumulation of APP in the phospholipid rich
fractions. Quantification of APP in the respective gradient fractions is represented in the
graph. 23% and 77% of total APP is present in the 30% and 40% fraction, respectively.
No APP was detected in the cholesterol rich domains (DRM) and the light 5% fraction.
These last results pave the way to undertake the functional study of the role of
phospholipids-rich membrane domains in APP proteolytic processing.
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3.1.3. RNAi against PE synthesis enzymes in HEK 293 cells efficiently affect
plasma membrane PE levels
To study the role of PE on APP proteolytic processing its membrane levels were
modified by treatment with RNAi. The effect of altered PE levels on APP was
studied by assaying the APP processing by ∀-, !- and #-secretase. Since APP
cleavage by #-secretase is the crucial step in the generation of A! peptide, the
interest was mainly focused on PE role in the regulation of this particular enzyme.
In addition to #-activity analysis, PE dependence of ∀- and !-secretase activity
was studied, as amyloidogenesis appears to be regulated by the interaction of all
three enzymes (see chapter 1.2.1.).
For the modification of membrane PE levels, following enzymes involved in the
PE synthesis pathway were blocked by RNAi: phosphoethanolamine
cytidylyltransferase (PECT), CDP-ethanolamine phosphotransferase (CEPT) and
ethanolamine kinase (ETNK). Cells were transfected with RNAi using
Lipofectamine 2000 reagent according to the manufacturer’s protocol and treated
for 48 hours. RNAi efficacy was tested after 48 hours by measuring membrane
PE levels in RNAi treated versus non-treated (control) cells (Figure 3.1.4. A). As
a control, cells were treated with RNAi directed against an irrelevant messenger
RNA (rat CYP7A1) (Figure 3.1.4. B). Cell membrane pellets isolation, followed by
lipid extraction, lipid separation by TLC and lipid measurement, revealed that
membrane PE level was approximately 40% lower in PECT, CEPT and ETNK
RNAi treated cells compared to the non-treated cells, whereas the membrane
content of cholesterol, ceramide, sphingomyelin, PC and PI did not significantly
differ in treated and non-treated cells (Figure 3.1.4. A). The treatment with the
control CYP7A1 RNAi had no effect on membrane lipid content (Figure 3.1.4. B).
To test whether RNAi treatment and PE depletion have a deleterious affect on
the cells, cell viability was assayed by measuring apoptosis and necrosis in low
PE cells versus control cells with wild type PE levels (Figure 3.1.4. C). As both
apoptosis and necrosis were not significantly different in PE depleted and control
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cells, I could rule out that PE depletion may have an unspecific effect on APP
proteolytic processing through inducing cell death.
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Figure 3.1.4. HEK 293 cells treated with RNAi, directed against enzymes involved
in PE synthesis pathway show a decrease of membrane PE levels. HEK 293 cells
were treated with RNAi against PECT, CEPT and ETNK and the control RNAi, directed
against rat CYP7A1.  After 48 hours of RNAi treatment cell membranes were isolated,
using the same amount of total protein as starting material. Membrane lipids were
extracted and analyzed by TLC. Lipid quantification is shown in the graph. (A) HEK cells
treated with the RNAi directed against PECT, CEPT and ETNK show approximately 40%
lower membrane PE content than non-treated cells. Membrane levels of cholesterol,
ceramide, sphingomyelin, PC and PI do not significantly differ in non-treated and RNAi
treated cells.  (B) HEK 293 cells, treated with the control, rat CYP7A1 RNAi, under the
same experimental conditions like the cells described in A, do not show any significant
changes in the membrane lipid composition in comparison to the non-treated cells.  (C)
Apoptosis levels, measured by TUNNEL assay have similar values, 9% of total cells, in
non-treated and PE depleted cells. Also necrosis, determined by Trypan blue staining,
was not enhaced by PE depletion. The amount of necrotic cells in control (non-treated)
and low PE cells was about 3% of total cells.
3.1.4. RNAi against PE synthesis enzymes in HEK 293 cells alter APP
cleavage efficacy
To determine whether PE depletion affects proteolytic processing of APP, low PE
HEK 293-wtAPP695 cells were analysed for the changes in APP cleavage by ∀-
!-, and #-secretase. Cleavage of APP by ∀- or alternatively by !-secretase leads
to generation and extracellular release of soluble APP peptides, sAPP∀ and
sAPP!, respectively, and the retention of corresponding membrane-anchored C-
terminal fragment, ∀CTF (C83) and !CTF (C99). Membrane-anchored C-terminal
fragments ∀CTF and !CTF, are both substrates for #-secretase that cleaves C83
and C99 within the membrane and derives nonamyloidogenic p3 and
amyloidogenic A!, respectively. Additionally to p3 and A!, #-secretase cleavage
releases AICD in the intracellular space.
To analyse the effect of PE depletion on ∀- and !-secretase cleavage of APP,
HEK 293 cells stably expressing wild-type APP695 were treated with RNAi
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directed against the enzymes: PECT, CEPT and ETNK, as described above.
Crude membrane pellets, from non-treated (control) and RNAi treated cells, were
resolved by the urea version of the Bicine/bis-Tris/Tris/sulfate SDS-PAGE
(Wiltfang et al., 1991). Western blot analysis was performed with ANTI-APP, C-
terminal antibody to visualize full length APP (fl APP) and the membrane-
anchored ∀CTF. !CTF fragment was detected by Anti-Human ! Amyloid [1-17]
antibody. In RNAi treated cells, with approximately 40% less membrane PE,
levels of APP-C-terminal fragment generated by !-secretase processing of APP,
revealed a 40-50% decrease compared to the cells with wild-type PE levels
(Figure 3.1.5. A). ∀CTF levels in low membrane PE cells were increased an
average of 50% over the control. In addition to ∀CTF analysis, ∀-secretase
activity was assayed by changes in the levels of secreted sAPP∀ .
Correspondingly to the increased ∀CTF levels, sAPP∀ content in the medium of
low PE cells was about 50% higher, with respect to the control cells (Figure 3.1.5.
A). To rule out, that the changes in the generation of ∀CTF and !CTF are due to
the alterations in APP expression the levels fl APP were determined in low PE
cells versus control. Quantification of fl APP normalized to the total amount of
∀Tubulin, revealed that, PE depletion in the membranes of HEK 293 cells did not
cause alterations in APP content. Control RNAi directed against rat CYP7A1 had
an effect neither on ∀CTF and !CTF nor on fl APP levels (Figure 3.1.5. B), which
excludes an unspecific effect of RNAi on APP proteolytic processing. Taken
together the results above indicate a specific effect of PE on ∀- and !-secretase
activity on APP.
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Figure 3.1.5. HEK 293 cells with low membrane PE show changes in APP
processing by -, - and -secretase.  (A) Activity of ∀-, !- and #-secretase in HEK
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293-wild-type APP695 cells was analysed after depletion of approximately 40% of
membrane PE by RNAi directed against PECT, CEPT and ETNK enzymes. For
determination of fl APP, ! and  ∀CTF’s crude membrane pellets isolated form non-
treated (control) and RNAi treated cells were subjected to the urea version of the
Bicine/bis-Tris/Tris/sulfate SDS-PAGE. Tubulin served as the loading control. The
amount of fl APP, determined by ANTI-APP C-terminal antibody does not significantly
differ in control and low PE cells. Membrane levels of !CTF fragment, determined by
Anti-Human !  Amyloid [1-17] antibody, were 40- 50% lower in PE depleted cells
compared to the control. Analysis of the membrane-anchored ∀CTF, visualized by ANTI-
APP C-terminal antibody revealed that the amount of ∀CTF in low PE cells was
approximately 50% increased with respect to the control cells. ∀CTF and !CTF
membrane levels, determined by densitometry were normalized to the amount of total
APP. Consistent to the elevated levels of ∀CTF, the amount of sAPP∀ in the medium
was about 50% higher than in the medium from the control cells. Immunoprecipitations
from extracellular medium were submitted to 10% Laemmli-PAGE and sAPP∀ visualized
by A! N-terminus specific antibody 1E8 (Nanotools). (A1) In HEK 293-SwedishAPP695
A!42 generation was analysed in ETNK RNAi treated cells versus control, by ELISA and
Western blotting using WO2 antibody. Compared to the non-treated cells, RNAi treated
cells show a decrease in A! generation of approximately 18%. Quantification of A! 42
peptide, depicted in the graph, revealed similar results in both assays. (B) Control RNAi
against rat CYP7A1 did not cause any alterations in full length APP levels and its
proteolytic processing by ∀- and !-secretase. The analyses of fl APP, ! and ∀CTF’s and
sAPP∀  were performed as described under A.  Quantifications are shown in the
respective graph.
After it was shown that membrane PE depletion is related to the changes in the
generation of ∀- and !-secretase products (Figure 3.1.5.), #-secretase activity
was analysed, measuring changes in the A! production. For the analysis of A!,
cell culture medium from the PECT, CEPT and ETNK RNAi treated and control
cells was collected and A! peptide recovered by immunoprecipitation with
Amyloid beta A4, amino-terminal-selective antibody 1E8 (Nanotools).
Subsequently immunoprecipitates were analysed on the urea version of the
Bicine/bis-Tris/Tris/sulfate SDS-PAGE, using the A! 1E8 antibody.
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The antibody detection of A! released into the extracellular medium from the
HEK 293-wild-type APP695 cells showed that the amount of peptide was not
sufficient to perform a proper quantification. In order to overcome this problem I
switched the A! analysis to the HEK cells, which overexpress human APP695
with the Swedish mutation (SweAPP695). This mutation in the APP gene
elevates the amount of generated A! that allows a valid quantification of the
peptide. PE levels in the membranes of HEK 293-SweAPP695 cells were
depleted by RNAi directed against the ETNK enzyme. Afterwards A! generation
was analysed by Western blotting and ELISA assay in low PE cells versus non-
treated (control) cells, with wild-type membrane PE levels. For Western blot
detection of A! peptide extracellular medium (the amount was standardized by
the protein amount) was re-suspended in sample buffer and resolved by the
16.5% SDS-PAGE. A! peptide was detected by using the WO2 antibody that is
raised against the residues 5-8 of A! region (Ida et al., 1996). The antibody
detection revealed that in HEK 293-SweAPP695 cells with depleted membrane
PE, the levels of the neurotoxic A! 42 species show a decrease of about 20% in
comparison to the control cells.  An additional quantification of human A! 42 in
the medium was performed using the highly sensitive kit “hAmyloid !42 ELISA
(HS)” (the GENETICS company) following the manufacturers instruction. The
results obtained by ELISA confirmed those from Western blot assay, revealing an
A! 42 decrease of approximately 20% after membrane PE depletion
(Figure3.1.5. A1).
Since the data in HEK 293 cells clearly show a correlation of membrane PE
levels and APP processing, experimental investigations were switched to a more
sophisticated Drosophila melanogaster in vivo system, in order to prove the
results obtained in mammalian in vitro system.
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3.2. Role of phosphatidyethanolamine (PE) in APP proteolytic
processing in Drosophila melanogaster
Drosophila melanogaster  is a widely used model system to study
neurodegenerative diseases, including Alzheimer’s disease. The strength of
Drosophila as an experimental organism relies on its powerful genetic tools (e.g.
large amount of transgenic lines and mutants), intensive genetic analysis of its
genome, short generation time and nevertheless the fact that Drosophila and
humans share many structurally and functionally related gene families, despite
their phylogenetic distance. One of these, in Drosophila and mammals, highly
conserved metabolic pathways is the mechanism of !-secretase activity
(Fossgreen et al., 1998, Takasugi et al., 2002). !-secretase has been shown to
play the main role in the generation of A∀ peptide, which forms senile plaques,
hallmark of AD pathology. Furthermore #-secretase-like activity has been
reported in Drosophila (Fossgreen et al., 1998, Loewer et al., 2004).
It is noteworthy that amyloid precursor protein-like protein APPL, a Drosophila
homologue of hAPP does not exhibit sequence similarities within the ∀-amyloid
region of APP (Selkoe, 1996), and !-cleavage of APPL has not been documented
(Rosen et al., 1990). But it has been shown that !-secretase in Drosophila
cleaves overexpressed hAPP and hAPP-C-terminal fragment in the similar
manner like in mammals, under generation of A∀ peptide and APP intracellular
domain (AICD) (Fossgreen et al., 1998, Takasugi et al., 2002, Loewer et al.,
2004).
Localization of APP and APP cleaving machinery on the membrane, suggests a
role of membrane lipids in the regulation of APP processing. As described in the
introduction, APP is processed by three proteases termed #∃, ∀∃ and !-
secretase. A∀ peptide is produced by the sequential cleavage of APP by ∀∃ and
!-secretase (Annaert and De Strooper, 2002).  This APP processing pathway is
termed amyloidogenic pathway. The production of an intact A∀ peptide is
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prevented by APP processing through the non-amyloidogenic pathway, in which
#-secretase cleaves APP within A∀ domain.
In chapter 3.1. I showed that in mammalian HEK 293 cells, membrane levels of
PE clearly correlate with processing of APP by #-, ∀- and !-secretase. Here I will
describe how the modulation of PE levels affect APP cleavage in vivo. For this I
have utilized Drosophila melanogaster, which, as mentioned above has been
shown to be valuable to study this phenomenon (Fossgreen et al., 1998,
Lichtenthaler et al., 1999, Struhl and Adachi, 2000, Takasugi et al., 2002, Francis
et al., 2002, Loewer et al., 2003, Guo et al., 2003, Doglio et al., 2006). Moreover,
Drosophila has been as well useful to study PE modulation (Pavlidis et al., 1994,
Dobrosotskaya et al., 2000, Nyako et al., 2001).
My in vivo, Drosophila-based validation work, started using embryonic Schneider-
2 (S2) cells grown in vitro, transiently transfected with SC100, an APP-C-
terminal-domain (C99) containing construct (SC100: M596-N695 of APP695, see
Material and Methods, Figure 2.1.). For the true in vivo studies I utilized
transgenic fly lines expressing the C-terminal fragment of hAPP (see Material
and Methods, Figure 2.2.) and the easPC8f mutant, defective in the gene for
ethanolamine kinase.
3.2.1.  Role of phosphatidyethanolamine (PE) in APP proteolytic processing
in Drosophila S2 cells
3.2.1.1. Phosphatidylethanolamine distribution in the cell membranes of
Drosophila S2 cells
Like in mammalian cells, !-secretase cleavage in Drosophila occurs on the
membrane. Phospholipids represent, besides sterols and sphingolipids, main
lipid species in Drosophila membranes. Barring the some differences, e.g. in the
length of fatty acyl chains, phospholipids in mammals and Drosophila have a
similar organization. PE, which is shown to correlate with the changes in APP
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processing in HEK 293 cells (see above), comprises 55% of total phospholipids
in Drosophila (Jones et al., 1992). Similar to the situation in mammalian cells,
structural properties of membrane lipids in Drosophila cells are consistent with
the ability to separate into sterol/sphingolipid rich, liquid ordered and phospholipid
rich, liquid disordered phase (Rietveld et al., 1999). Ergosterol/sphingolipid rich
domains in Drosophila cells have been shown to be insoluble in nonionic
detergent at 4oC, other than phospholipid rich membrane domains, which are
detergent soluble.
In order to study the role of PE in hC99 processing its membrane distribution in
S2 cells was determined by density gradient centrifugation. S2 membranes were
solubilized for 1 hour at 4oC in a 1% Triton X-100 containing buffer and
subsequently loaded on OptiPrep gradient, to separate detergent resistant
microdomains (DRM) from detergent soluble fractions (non-DRM).  Drosophila
melanogaster Flotilin (FlotilinDm), which is closely related to the raft associated,
mammalian Flotillin-1 (Galbiati et al., 1998), was used to identify DRM or raft
microdomains. For the identification of DRM, I performed a gradient phase
separation by 120.000 x g at 4oC for 18 hours. Subsequently, membrane pellets
from each fraction were extracted, re-suspended in sample buffer and loaded to
12% SDS-PAGE. Detection of FlotilinDm was performed by Western blotting using
Flotillin-1 antibody. FlotilinDm was significantly enriched in the interphase between
5% and 30% OptiPrep gradient fractions (Figure 3.2.1.). This data, together with
ergosterol enrichment in the 5%-30% fraction interphase (Figure 3.2.2.), indicates
flotation density of DRM in this gradient fraction.
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Figure 3.2.1. Drosophila Flotilin (FlotilinDm) is abundant in detergent insoluble
membrane microdomains (DRM) of S2 cells. Distribution of FlotilinDm was analysed by
density gradient centrifugation of S2 membranes, solubilized for 1 hour at 40C in a 1%
Triton X-100 containing buffer. OptiPrep gradient centrifugation was performed at
120,000 x g for 18 hours at 40C. After separation of raft and non-raft microdomains,
gradient fractions were collected. Cell membranes of each fraction were isolated by 100,
000 x g, resuspended in sample buffer and subjected to 12% SDS-PAGE. As depicted in
the graph, 33% of total FlotilinDm was present in the interphase between 5% and 30%
gradient fraction. Measurement of FlotilinDm levels in other gradient fractions show that
27% and 40% of total FlotilinDm is localized in 30% and 40% fractions, respectively. No
FlotilinDm was detected in the light 5% fraction.
To determine PE distribution in S2 membranes, cell membrane pellets,
solubilized in 1% Triton X-100, were separated in OptiPrep gradient as described
above. After density centrifugation, membranes from each gradient fraction were
isolated by 100,000 x g, and membrane lipids extracted according to Bligh and
Dyer (1959). Subsequent analysis of PE distribution by TLC shows that PE is
equally distributed all over the gradient, while ergosterol enriches in the 5%-30%
interphase, consistent to the FlotilinDm localization. The results concerning the
membrane distribution of PE and ergosterol obtained in S2 cells were similar to
those in mammalian cells. The ratio of total PE is 0.75 in non-rafts, while its
portion in rafts averages only 0.25. Other than PE, ergosterol is abundant in raft
fraction with 0.45 of its total membrane content.
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Figure 3.2.2. In Drosophila S2 cells 75% of total membrane PE is present in non-
raft fraction. S2 cell membranes were solubilized with 1% Triton X-100 at 40C and
loaded on OptiPrep gradient to determine PE distribution. After separation of detergent
soluble from detergent insoluble membranes by density centrifugation, membranes from
each gradient fraction were isolated by 100, 000 x g centrifugation and analysed by TLC.
The ratios of total membrane PE in respective gradient fraction, which are depicted in
the graph, show that all gradient fractions contain similar amount of approximately 25%
of total membrane PE. Non-raft domains, encompassing the 5%, 30% and 40%
fractions, contain 75% of total membrane PE. Contrariwise, ergosterol is with 45% of its
total amount strongly enriched in the raft fraction, identified by FlotilinDm in the 5%-30%
interphase. In 5%, 30 % and 40% fractions ergosterol was present with 13%, 20% and
22%, respectively.
3.2.1.2. Localization of hAPP (hC99) in the cell membranes of Drosophila S2
cells
To investigate, whether in S2 cells, membrane PE plays a role in APP
processing, as shown in HEK 293 cells, the distribution/localization of hC99 in the
membranes of S2 cells was analysed. S2 cells were transiently transfected with
hAPP695 C-terminal-domain (hC99) containing construct (SC100, Maryama et
al., 1994). The transfection was performed with Calcium Phosphate method,
according to the manufacturer’s protocol (Invitrogen). 72 hours after transfection,
cell membranes were solubilized in 1% Triton X-100 and submitted to the
OptiPrep gradient to determine hC99 distribution along the gradient.  After 18
hours centrifugation by 120,000 x g, gradient fractions were collected, membrane
extracts of each fraction isolated by 100,000 x g centrifugation and subjected to
the urea version of the Bicine/bis-Tris/Tris/sulfate SDS-PAGE. The localization of
hC99 was determined by immunostaining with ANTI-APP C-Terminal antibody.
As depicted in the Figure 3.2.3., about 84% of total hC99 was detected in 40%
gradient fractions. 30% fraction contains 16% of total hC99, whereas no hC99
was detected in 5% and DRM fraction. Like in mammalian cells, localisation of
hAPP (hC99) in Drosophila S2 cells is mainly restricted to the phospholipid rich
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fraction, unlike Flotilin and ergosterol distribution, which are significantly enriched
in DRM fraction.
Figure 3.2.3. Overexpressed hC99 is mainly enriched in the non-raft microdomains
of Drosophila S2 cells. Raft and non-raft microdomains of S2 cells overexpressing
hC99, were isolated by OptiPrep gradient centrifugation. Subsequently cell membranes
from each fraction were isolated, resuspended in sample buffer, resolved by the urea
version of the Bicine/bis-Tris/Tris/sulfate SDS-PAGE and stained with ANTI-APP C-
Terminal antibody, to analyse the localization of hC99.  Quantification, shown in the
graph, revealed that 84% of total hC99 is present in 40% fraction. Approximately 16% of
hC99 was detected in 30% fraction, whereas no hC99 was found DRM and 5% gradient
fractions.
Enrichment of hC99 within the phospholipid rich membrane core strongly
suggests an important role of those lipids in C99 processing. Among all
phospholipids PE appears most interesting regarding its role in cellular
processes. Moreover PE constitutes 55% of total phospholipids in Drosophila
membranes.
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3.2.1.3.   Altered membrane PE levels in Drosophila S2 cells correlate with
changes in hC99 processing
The fact that, in mammalian and in Drosophila cells, hAPP (hC99) preferentially
colocalizes with phospholipid rich membrane domains, strongly indicates the role
of those lipids in the regulation of APP processing. In Drosophila, in vitro and in
vivo systems, PS-dependant !-secretase activity has been shown to be highly
conserved and to cleave overexpressed hAPP (Fossgreen et al., 1998, Takasugi
et al., 2002, Loewer et al., 2004). Besides !-secretase cleavage, hAPP in
Drosophila is processed by #-secretase-like activity, that generates a ~ 10-kDa
polypeptide comigrating with C83 fragment of mammalian cells. (Fossgreen et
al., 1998, Takasugi et al., 2002, Loewer et al., 2004). Processing of hAPP-Ct by
Drosophila !-secretase generates A∀ peptide and the APP intracellular domain
(AICD).
In order to determine the role of PE in APP processing by !-secretase, A∀ levels
were analyzed in low PE cells versus control cells with wild type membrane PE
levels. In addition to A∀ generation I assayed the changes in hC99 and #-stub-
like fragments, as they correlate with the levels of !-secretase activity. To deplete
membrane PE, S2 cells were treated with RNAi directed against enzymes
involved in the CDP-Ethanolamine pathway: phosphoethanolamine
cytidylyltransferase (PECT) and ethanolamine kinase (ETNK). At first Drosophila
S2 cells were transiently transfected with hC99. 24 hours after transfection cells
were treated with RNAi for 48 hours. Such treatment abolishes the corresponding
endogenous mRNA selectively through RNAi and leads to the loss of respective
enzyme activity. After 48 hours of RNAi treatment, membrane pellets from
treated and non-treated (control) cells were isolated by 100,000 x g and after lipid
extraction analysed by TLC. Membrane lipid analysis revealed that membrane
PE content in PECT and ETNK RNAi treated cells was about 40% lower with
respect to non-treated cells (Figure 3.2.4. A). In contrast, membrane content of
ergosterol, ceramide, PECeramide, phosphatidylcholine (PC) and
phosphatidylinositol (PI) was not significantly altered compared to the non-treated
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cells (Figure 3.2.4. A). To exclude an unspecific effect of RNAi on membrane PE
content S2 cells, transiently transfected with hC99 were treated for 48 hours with
a control RNAi, directed against rat CYP7A1 mRNA. Membrane isolation, lipid
extraction and analysis were carried out under the same experimental conditions
like above. As shown in the Figure 3.2.4. B, control RNAi did not cause any
changes in the membrane lipid composition of S2 cells. Cell viability, tested by
apoptosis and necrosis in low PE versus control cells, revealed that the levels of
cell death in PE depleted and control cells did not significantly differ, i.e. PE
depletion does not have a deleterious effect on S2 cells (Figure 3.2.4. C).
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Figure 3.2.4. S2 cells show approximately 40% decreased membrane PE levels
after treatment with RNAi directed against PECT and ETNK enzymes.  (A) 48 hours
after PECT and ETNK RNAi treatment, extracts from S2 cells overexpressing hC99 were
centrifuged for 1 hour at 100,000 x g in order to isolate cell membrane pellets.
Membrane lipids extracted from crude membranes of RNAi treated and non-treated cells
were analysed by TLC. Lipid quantification in RNAi treated cells versus non-treated
(control) cells revealed that PECT and ETNK RNAi treatment induced a decrease of
membrane PE of approximately 40% with respect to the non-treated cells.  Ergosterol,
ceramide, PECeramide, PC and PE do not show significantly different membrane levels
in RNAi treated and non-treated cells. (B) S2 cells treated with control rat CYP7A1 RNAi,
under same experimental conditions as described above, do not exhibit any changes in
their membrane lipid levels in comparison to the non-treated cells. Quantifications of
membrane lipid content in RNAi treated cells versus control are shown in the graph. (C)
Levels of apoptosis and necrosis measured in low PE cells did not reveal significant
differences to control cells. As shown in the graph the percentage of apoptotic cells was
about 8% of total cells in PE depleted cells and the cells with wild-type PE content. Also
the level of necrosis in both, low PE and control cells was about 5% of total cell amount.
After it was shown, that PECT and ETNK RNAi treatment specifically leads to PE
depletion, without significant alterations in membrane content of other major
lipids and without affecting cell viability, I addressed the question, whether PE
depletion causes changes in hC99 proteolytic processing. For the analysis of
membrane-anchored C99 and #-stub-like fragments, crude membrane pellets
from non-treated and low membrane PE cells were isolated, subjected to the
urea version of the Bicine/bis-Tris/Tris/sulfate SDS-PAGE and stained with ANTI-
APP, C-Terminal antibody. Immunoblot analysis showed a decrease of
approximately 65% in C99 and #-stub-like levels, in low PE cells with respect to
the non-treated (control) cells (Figure 3.2.5., left panel). Both membrane-
anchored fragments, C99 and #-stub-like are substrates for !-secretase and the
decrease in their membrane levels indicates that they are longer processed by !-
secretase than under control conditions. This observation indicates an elevated
!-secretase activity but as C99 and #-stub-like membrane levels are only indirect
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indicators for !-secretase activity, I analysed the amount of A∀ in order to directly
assay the effect of PE depletion on  !∃activity.
A∀ peptide was immunoprecipitated from the extracellular medium of the control
and PE depleted cells, using Amyloid beta A4, amino-terminal-selective antibody
1E8 (Nanotools) and afterwards analysed on the urea version of the Bicine/bis-
Tris/Tris/sulfate SDS-PAGE. As already indicated by C99 and #-stub-like
analysis, A∀ generation changes dramatically after membrane PE depletion.  The
amount of total A∀ in low PE cells averages 80% over the control (Figure 3.2.5.
B). PE depletion did not alter the rates of single A∀ species in relation to the total
A∀ content. Figure 3.2.5. (right panel) depicts different A∀ species, generated
depending on !-secretase cleavage site. “A∀ X” represents an A∀ peptide species
that is not defined yet (personal comment from Dr. Wiltfang).
Crude membrane pellets and the cell culture medium from CYP7A1 RNAi treated
and non-treated cells were analysed for C99, # -stub-like fragment and
A∀ as described above.  Western blot analyses revealed that rat CYP7A1 RNAi
did not induce any significant changes neither in C99 and #-stub-like nor in
A∀ generation (Figure 3.2.5., see left and right panel).
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Figure 3.2.5. In S2 cells, membrane PE depletion by PECT and ETNK RNAi leads to
alterations in hC99 processing by -secretase. (left panel) Analysis of crude
membrane pellets, isolated from PECT and ETNK RNAi treated S2 cells show altered
levels of C99 and #-stub-like fragments versus control cells. Both membrane-anchored
fragments were analysed using urea version of the Bicine/bis-Tris/Tris/sulfate SDS-
PAGE and ANTI-APP C-Terminal antibody. In comparison to the non-treated cells,
membranes of PECT and ETNK RNAi treated cells show about 65% lower level of C99
and #-stub-like fragments. Densitometry measurements were normalized to the amount
of # Tubulin. (right panel) Immunoprecipitations from extracellular medium were
resolved by the urea version of the Bicine/bis-Tris/Tris/sulfate SDS-PAGE and visualized
using Amyloid beta A4, amino-terminal-selective antibody 1E8. The densitometry
analysis revealed that total A∀ content in PE depleted cells averages approximately 80%
over the control. The ratios of single A∀ species (A∀ 1-37, A∀ 1-38, A∀ 1-39, A∀ 1-40, A∀
1-42, A∀ X) do not significantly differ in control and low PE cells.  (left and right panel)
Control treatment, performed under the same experimental conditions as described
above with rat CYP7A1 RNAi had a significant effect neither on levels of membrane-
anchored APP fragments, nor on generation of A∀ peptide.
Increased generation of A∀ peptide as well as decreased C99 and #-stub-like
membrane levels, described above, indicate an elevated activity of !-secretase
on APP caused by PE depletion. These data contradict the results obtained in
mammalian system, where I had shown that reduction of membrane PE content
leads to decreased APP proteolytic processing by !- and ∀-secretase. One
possibility for the discrepancy would be that, because of being embryonic,
Schneider-2 cells represent PE-mediated modulation of APP at the embryonic,
but not mature stage of life.  Another possibility is that Drosophila cells have in
vitro requirements not relevant in the more complex situation of the in situ
scenario. Either possibility could be addressed by looking at the processing of
hC99 in Drosophila in vivo.  The results of this analysis are described next.
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3.2.2. Role of phosphatidylethanolamine (PE) in APP proteolytic processing
Drosophila in vivo system
As already mentioned above, hAPP processing in Drosophila system has been
described in several studies (Fossgreen et al., 1998, Lichtenthaler et al., 1999,
Struhl and Adachi, 2000, Loewer et al., 2003, Guo et al., 2003, Doglio et al.,
2006). To study the role of PE in APP processing, I have utilized Drosophila
melanogaster transgenic strains expressing hAPP-C-terminal (APP-Ct) fragment
initiating downstream of the ∀-secretase cleavage site. These !-reporter flies
were crossed with easPC80f mutant, defective in the gene for ethanolamine
kinase.
One of Drosophila transgenic lines used in this study is GMR-APP-GAL4, UAS-
GRIM which acts as a reporter of !-secretase activity in the fly eye (Guo et al.,
2003). These reporter flies, allow the studying of endogenous levels of !-
secretase activity, using a nonessential neuronal tissue, adult fly eye.  As !-
secretase substrate serves a chimeric type-I transmembrane protein, which
contains a N-terminus, with a cleavable signal sequence followed by human
APP-C-terminal fragment to the ∀-secretase cleaving site (see Material and
Methods, Figure 2.2.). The protein is targeted to the secretory pathway by the N-
terminal signal sequence.  On its C-terminal end hAPP-Ct is fused to the yeast
transcription factor GAL4. APP-Ct-GAL4 is specifically expressed in the eye
under control of eye specific GMR promoter. The reporter flies carry additionally
to hAPP-Ct-GAL4, a !-secretase reporter output construct, UAS-GRIM, that
consists of a GAL4-responsive transcriptional cassette driving the expression of
the Drosophila cell death activator GRIM (Chen et al., 1996). After !-secretase
cleavage, APP-C-terminal fragment downstream of the !-cleavage site moves
together with GAL4-VP16 to the nucleus, and triggers the transcription of cell
lethal gene GRIM, through UAS activation (Figure 3.2.8. G) Activation of Grim
transcription by !-secretase processing of hAPP-Ct, promotes cell death in the fly
eye, so that the size of the eye and the roughened surface correlate with the level
of endogenous !-secretase activity.
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To address the role of PE in APP processing in Drosophila in vivo system, !-
reporter flies were crossed with easPC80f mutants, for the purpose of generating
low PE flies expressing hAPP-Ct. EasPC80 mutants have a defect in enzymatic
activity of ethanolamine kinase (ETNK), which is the first enzyme in the synthesis
of PE via CDP-ethanolamine pathway (Kennedy, 1957; Figure 1.4.). ETNK has
been located on the gene easily shocked (eas) (Pavlidis et al., 1994), localized
on the X chromosome. EasPC80 mutation is a frame shift mutation based on a 2bp
deletion in easPC80 gene at nucleotide position 1004-1005, which introduces a
stop codon in-frame at nucleotide position 1078. These mutants, defective in eas
gene lack completely highly conserved kinase domain, which is required for
ETNK enzymatic activity. Correspondingly to ETNK loss of function, easPC80
mutants have a decreased PE levels compared to the wild-type flies. EasPC80
homozygous are viable and under most conditions the flies do not show any
observable abnormalities, regarding development, viability, behaviour and
electrophysiology (Pavlidis et al., 1994).
In order to prove the effect of membrane PE on APP processing by !-secretase
in Drosophila in vivo system, easPC80f mutants were crossed with GMR-APP-
GAL4, UAS-GRIM transgenic flies. At first, membrane PE levels were determined
in easPC80f homozygous versus wild-type flies. Additionally, PE levels in the
transgenic flies, which served as control for !-activity levels, were measured in
comparison to wild-type flies. TLC analysis of membrane lipid composition
showed that easPC80f mutants have about 50% lower membrane PE levels than
the wild-type flies. Ergosterol, ceramide, PECeramide, PC and PI membrane
levels, in contrary, are not significantly different in mutant and wild-type flies
(Figure 3.2.6. A). Transgenic and wild-type flies have a consistent membrane
lipid composition, as shown in the Figure 3.2.6. B.
Results
67
Figure 3.2.6. EasPC80f homozygous flies show a low membrane PE level versus
wild-type flies, while membrane PE levels in -reporter flies do not differ from
these in wild-type flies. Membrane pellets from homogenates of 10 flies were isolated
by 100,000 x g centrifugation, using the same amount of total protein as starting
material. Afterwards membrane lipids were extracted and analysed by TLC. (A) TLC
analysis of membrane lipid content in easPC80f homozygous, lacking ETNK enzyme
activity, revealed about 50% lower PE level in the membranes of these flies in
comparison to the wild-type (Oregon R) flies. Mutants and control (wild-type) flies did not
significantly differ in their membrane content of ergosterol, ceramide, PECeramide, PC
and PI. Quantifications are represented in the graph. (B) Membrane lipid content in !-
reporter flies: GMR-APP-GAL4, UAS-GRIM/+ and APP-GAL4-VP16, UAS-cd8-GFP/+
versus wild-type flies shows similar values for PE, ergosterol, ceramide, PECeramide,
PC and PI. For quantifications see graph.
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Progeny, generated by crossing easPC80f mutants with GMR-APP-GAL4, UAS-
GRIM transgenic flies with following genotype: easPC80f/Y; GMR-hAPP-Ct-GAL4,
UAS-GRIM/+ and easPC80f/easPC80f; GMR-C99-GAL4, UAS-GRIM/+, was
assayed for membrane lipid content. Because hAPP-Ct is specifically expressed
in the eye of the transgenic flies, membrane PE level in the head appears to be
relevant for !-secretase activity on APP. To determine membrane PE content,
cell membranes were isolated by 100,000 x g from homogenates of 20 fly heads
and analysed by TLC after lipid extraction. TLC analysis and subsequent
quantification of membrane lipid content revealed a 50-60% lower membrane PE
level in the progeny, which are !-reporter flies homozygous for easPC80 mutation,
compared to the control flies, reporter flies with wild-type PE level. Other
membrane lipids, like ergosterol, ceramide, PECeramide, PC and PI did not
significantly alter in mutants and control flies (Figure 3.2.7. A).
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Figure 3.2.7.  Membrane PE content is 50-60% lower in easPC80f/Y; GMR-hAPP-Ct-
GAL4, UAS-GRIM/+ and easPC80f/easPC80f; GMR-hAPP-Ct-GAL4, UAS-GRIM/+
mutants, than in the transgenic flies without easPC80 mutation, GMR-hAPP-Ct-
GAL4, UAS-GRIM/+.  (A) Membrane lipids extracted form the membranes of 20 fly
heads were analysed by TLC and subsequently quantified for PE, ergosterol, ceramide,
PECeramide, PC and PI amount. Membrane PE levels show a significant decrease of
50-60% in reporter flies carrying easPC80 mutation compared to the control flies (GMR-
hAPP-Ct-GAL4, UAS-GRIM). Other analysed lipids have similar membrane content in
easPC80 homozygous and control flies.  (B) Membrane lipids isolated, under the same
experimental conditions as described in A, have been assayed for their content in
easPC80 homozygous expressing GMR-GAL4, UAS-G/RPR/+ versus GMR-GAL4, UAS-
G/RPR/+ flies without easPC80 mutation (control). Membrane lipid quantification shows
approximately 55% lower PE level in mutant flies with respect to the control flies. PE was
only lipid, which shows altered levels in easPC80 mutants, while ergosterol, ceramide,
PECeramide, PC and PI contents do not significantly differ in comparison to the control
flies. All quantifications are depicted in the respective graph.
These flies, which have low membrane PE level, relying on easPC80 mutation and
show retinal degeneration phenotype due to GMR-APP-Ct-GAL4, UAS-GRIM/+
transgene expression were analysed for the role of membrane PE in !-activity. To
assess the role of membrane PE in the modulation of !-secretase activity,
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easPC80f homozygous, carrying chimeric protein hAPP-Ct-GAL4-VP16 and the
UAS-GRIM output were assayed for levels of retinal cell death versus control
flies. Since eas gene is localized on the X chromosome, homozygous have been
generated with eas mutation on one (easPC80f/Y; GMR-hAPP-Ct-GAL4, UAS-
GRIM/+) and on both alleles (easPC80f/easPC80f; GMR-hAPP-Ct-GAL4, UAS-
GRIM/+), to verify the results. Both homozygous have the same genetic
background for ETNK activity and show corresponding membrane PE levels
(Figure 3.2.7. A).
Effect of altered membrane PE levels on !-secretase activity was analysed by the
size of the fly eye and the size of roughened exterior eye surface. Both small
eyes and roughened exterior eye surface are indicative for retinal cell death and
correlate with the level of endogenous !-secretase activity. Control flies,
transgenic for GMR-hAPP-Ct-GAL4, UAS-GRIM with a wild-type membrane PE
level (3.2.6. B and 3.2.7. A), show certain level of retinal cell death due to the
normal levels of endogenous !-secretase activity. Approximately 70% of total eye
surface is roughened in the !-reporter control flies and the eye size is compared
to the wild-type eye about 20% decreased (Figure 3.2.8. A, B). EasPC80f
homozygous, expressing GMR-hAPP-Ct-GAL4, UAS-GRIM were compared to
the control flies measuring adult eye size and eye roughness, which was
calculated as a percentage of the total eye surface. Retinal cell death, present in
the control flies is almost eliminated and the eye size is restored to normal by
introducing easPC80f mutation (Figure 3.2.8. B, C, D).  Roughened eye surface in
easPC80f homozygous averages only 10-15% of the total eye, compared to the
70% in control eye. Eye size in the flies with easPC80 mutation is an average of
15% over the control, i.e. only 5% smaller then the wild-type eye, corresponding
to decreased !-secretase activity and less expression of the cell lethal gene.
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Figure 3.2.8. Levels of -secretase activity, measured by retinal cell death are
significantly lower in reporter flies with easPC80 mutation than in control -reporter
flies.  Light microscope images of adult fly eyes of various genotypes. The genotypes
are as follows: (A)  Oregon R (wild-type) (B) GMR-APP-GAL4, UAS-GRIM/+, (C)
easPC80f/Y; GMR-APP-GAL4, UAS-GRIM/+ (D) easPC80f/easPC80f; GMR-hAPP-Ct-GAL4,
UAS-GRIM/+. !-secretase activity was measured by cell death levels in control reporter
flies (GMR-hAPP-Ct-GAL4, UAS-GRIM; B) versus reporter flies homozygous for easPC80
mutation (C, D). Retinal cell death was scored by quantification of eye size and the size
of roughened eye surface. Quantifications of roughened eye surface revealed that the
retinal cell death in mutant flies (C, D) was almost eliminated and so only 10-15% of eye
surface were affected compared to 70% of roughened eye in control flies with wild-type
levels of !-activity.  Also the eye size in easPC80 homozygous mutants was similar to the
one in Oregon R flies and approximately 15% bigger than in control flies. Measurement
of retinal cell death in GMR-GAL4, UAS-G/RPR/+ control flies (E) versus easPC80
mutants expressing GMR-GAL4, UAS-G/RPR/+ constructs (genotype: easPC80f/easPC80f;
GMR-GAL4, UAS-G/RPR/+, (F)) revealed that the size of roughened eye surface and
the eye size do not differ in mutants and control flies. Like in GMR-GAL4, UAS-G/RPR
control flies easPC80 mutants show approximately 90% of roughened eye surface. The
eye size is 30% smaller than in the wild-type eye, in both mutant and control fly. (G)
Schematic illustrating a !-secretase reporter. The reporter contains two components: the
chimeric protein (APP-CT (A∀ (red) + Ct (black bar)) appended to the GAL4-VP16) that
serves as a !-secretase substrate and the UAS-GRIM construct as an output. APP-
GAL4-VP16 is specifically expressed in the eye under the control of GMR promoter. In
the absence of !-secretase activity APP-GAL4 remains attached to the membrane and is
disabled to enter the nucleus and activate the transcription of the cell lethal gene GRIM.
In the presence of !-secretase activity, cleavage of APP releases a fragment consisting
of APP-Ct initiating downstream of the !-cleavage site and GAL4-VP16. This fragment
translocates to the nucleus and activates GRIM transcription, thereby promoting retinal
cell death through UAS activation.
To rule out an unspecific effect of easPC80 mutation on GRIM expression, easPC80f
mutants were crossed with the GMR-GAL4, UAS-G/RPR flies that do not contain
hAPP-Ct chimeric protein. Like in !-secretase reporter system, in control flies
Results
73
GAL4-VP16 fusion construct is specifically expressed in the eye under GMR
promoter and the flies show small eye phenotype. Since in control flies, GAL4 is
not fused to hAPP-Ct, thus not under the control of !-secretase, true modifiers of
!-secretase should alter the eye size of the reporter flies containing APP but not
those of control flies, that lack APP. Flies carrying the easPC80 mutation, which
has been shown to correlate with altered !-secretase activity, were crossed with
control flies and analysed for membrane PE content and the level of retinal cell
death.
Progeny, homozygous for easPC80 mutation, containing GMR-GAL4, UAS-G/RPR
constructs show about 55% decreased PE level compared to the control GMR-
GAL4, UAS-G/RPR  flies. Membrane levels of ergosterol, ceramide,
PECeramide, PC and PI do not differ in mutant and control flies (Figure 3.2.7. B).
Although easPC80 mutants have a significantly altered membrane PE level, the
comparison of retinal cell death in easPC80 mutants versus control flies, revealed,
that both eye size and the size of roughened eye surface are not significantly
different (Figure 3.2.8. E, F). This observation indicates a specific effect of
easPC80 mutation through lowering of PE level, on !-secretase activity.
To confirm the results obtained with GMR-APP-GAL4, UAS-GRIM transgenic
system, APP-GAL4-VP16, UAS-cd8-GFP flies were utilized as transgenic
readout to study !-secretase activity. This system is based on the fusion of GAL4
DNA-binding domain and the VP16 activator domain to the C-terminal domain of
hAPP (hAPP-Ct) (Figure 2.2.). Upon !-secretase processing of hAPP-Ct, APP-
Ct-GAL4-VP16 is released from the membrane, and it moves to the nucleus
where it drives the expression of UAS-cd8-GFP reporter gene in a ligand-
dependent manner (Struhl and Adachi, 2000) (Figure 3.2.10. C). Processing
event of hAPP-Ct by !-secretase is visualized by expression of the green
fluorescent protein (GFP), which takes place in the whole body.
To study the modulatory role of PE on !∃secretase activity, PE levels in APP-
GAL4-VP16, UAS-cd8-GFP flies have been modified, by crossing these flies with
easPC80f mutants. Subsequently GFP expression levels were determined in
progeny homozygous for easPC80 mutation. APP-GAL4-VP16, UAS-cd8-GFP
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flies, which have wild-type PE levels (Figure 3.2.6. B), served as control for !-
activity. As described in the Figure 3.2.6. A, easPC80 mutants show approximately
50% decrease in membrane PE content in comparison to the wild-type flies,
whereas the content of other membrane lipids does not significantly differ in
mutant and wild-type flies.
Before initiating analysis of !∃secretase activity, easPC80 homozygous progeny
generated by crossing APP-GAL4-VP16, UAS-cd8-GFP transgenic flies and
easPC80f mutants were assayed for the membrane lipid composition. Cell
membranes from homogenates of 10 fly bodies were prepared by centrifugation
at 100,000 x g. Subsequently membrane lipids were extracted and analysed by
TLC (see Materials and Methods). TLC lipid analysis revealed that the level of
membrane PE in progeny, homozygous for easPC80 gene was 50% lower with
respect to control flies. Levels of other membrane lipids: ergosterol, ceramide,
PECeramide, PC and PI, did not significantly differ in the cell membranes of
easPC80 mutant and the control (Figure 3.2.9.).
Figure 3.2.9. APP-GAL4-VP16, UAS-cd8-GFP/+ flies, homozygous for easPC80 gene
show decreased PE levels compared to the control flies. TLC analysis showing that
only membrane PE levels reveal significant decrease of about 50% in easPC80
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homozygous (easPC80fY; APP-GAL4-VP16, UAS-cd8-GFP/+) compared to the control
flies (APP-GAL4-VP16, UAS-cd8-GFP/+), whereas other lipids (ergosterol, ceramide,
PECer, PC, PI) have similar membrane levels in both, mutant and control reporter flies.
Values from membrane lipid quantification are depicted in the graph.
Whether PE depletion in the membranes of reporter flies, homozygous for easPC80
gene, causes altered !-secretase processing of hAPP-Ct was assayed by the
GFP expression, measured by fluorescence intensity and Western blotting.
Transcription of GFP reporter gene is triggered by translocation of the C-terminal
end of hAPP-Ct together with GAL4-VP16 to the nucleus after !-secretase
cleavage, so that GFP fluorescence level is a direct indicator of !-secretase
activity (Figure 3.2.10. C). In the absence or decrease of !-activity, hAPP-Ct-
GAL4-VP16 remains at the membrane and therefore is unable to enter the
nucleus and activate GFP transcription. Analyses of GFP levels by fluorescence
intensity and Western blotting were performed after adult flies were heat shocked
at 370C for 1 hour and placed at 250C to allow GFP expression. Strong GFP
fluorescence intensity, present in control reporter flies is an evidence for an
active !-secretase enzyme, under control conditions. After altering the membrane
PE levels in reporter flies by introducing easPC80 mutation, GFP levels decrease
dramatically. Fluorescence intensity in GFP reporter flies with easPC80 mutation is
approximately 65% lower than in the control flies (Figure 3.2.10. A).
Additionally GFP levels in control and homozygous mutants were measured by
Western blot analysis. 10 adult flies were homogenized in lysis buffer, subjected
to 15% SDS page and stained with GFP-Peptide Antibody  (BD Biosciences). As
shown in the Figure 3.2.10. B, GFP expression, which corresponds to
endogenous !-secretase activity, is about 65% lower in mutant flies with respect
to the control flies.
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Figure 3.2.10. GFP expression in easPC80 homozygous flies, transgene for APP-
GAL4-VP16, UAS-cd8-GFP is dramatically decreased compared to the reporter
control flies.  (A) GFP signal in Drosophila transgenic flies with following genotypes:
APP-GAL4-VP16, UAS-cd8-GFP/+ and easPC80f/Y; APP-GAL4-VP16, UAS-cd8-GFP/+,
was measured 12h after heat-shock-induced activation of the APP-GAL4-VP16
construct. GFP expression measured by fluorescence intensity in the entire fly shows a
decrease of about 65% in mutants with respect to control flies. (B) An additional analysis
of GPF expression by Western blot analysis revealed, similar to the fluorescence
intensity measurements, an approximately 65% lower GFP level in easPC80 mutant
versus control reporter flies. Tubulin served as the loading control. (C) Schematic
illustrating a !-secretase reporter. This system is based on a chimeric protein (APP-C-
terminal fragment, consisting of: A∀ (red) + Ct (black bar)) appended to the transcription
factor GAL4-VP16 (GV) downstream of APP-Ct transmembrane domain and the UAS-
GFP construct as an output. In the absence of !-secretase activity APP-GV remains
tethered at the membrane and no GFP expression will be observed.  !-secretase activity
releases APP-C-t-GV from the membrane that translocates to the nucleus and triggers
GFP expression through UAS activation.
C
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These data confirm the results obtained with the GMR-APP-GAL4, UAS-GRIM
transgenic system and indicate a correlation of low membrane PE levels, caused
by easPC80 mutation, with the decreased level of !-secretase activity in
Drosophila.
4. Discussion
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Present study shows that membrane PE levels correlate with alterations in APP
processing. This finding is supported by the observation that APP localization is
largely restricted to the phospholipid rich liquid disordered phase. Other than
APP, the part of its cleaving machinery, involved in amyloidogenic pathway
colocalizes with raft-like, liquid ordered membrane microdomains (Li et al., 2000,
Wahrle et al., 2002, Ehehalt et al., 2003, Rodriguez et al., 2004, Vetrivel et al.,
2004) though it is also clear that it is also present in the non-raft regions of the
membrane. In contrast to !- and ∀-secretase, #-secretases have not been linked
to raft microdomains (Ehehalt et al., 2003). Given these facts APP proteolysis
appears to be regulated by differential partitioning into distinct membrane sub-
domains, rafts and non-rafts. In theory, such spatial segregation could determine
the degree of access of secretases to the substrate and thus the degree of
amyloid generation.
A key to understanding amyloidogenesis is to establish how the access of the
secretases to APP is modulated. In this study I could demonstrate, by using
Drosophila and mammalian model system, that the non-raft phospholipid rich
membrane domains are implicated in processing of amyloidogenic APP. By no
means this comes to contradict previous work strongly indicative of the
involvement of rafts (Ehehalt et al, 2003); simply that non-rafts do also
participate. From here one could conclude that APP proteolytic processing relies
on dynamic interaction of raft and non raft membrane domains and that both rafts
and non-rafts are important regulators of its cleavage by #-, !- and ∀ -secretase.
4.1. In mammalian HEK 293 cells membrane PE modulates
proteolytic processing of APP by its cleaving enzymes -, - and
-secretase
In the cellular membranes of HEK 293 cells, APP is mainly restricted to the
phospholipid membrane core, which strongly indicates the involvement of these
lipids in the regulation of APP cleavage.  Indeed the analysis of APP processing
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enzymes revealed significant changes in their activity in low membrane PE cells
compared to the cells with wild-type membrane PE content.
For the purpose of analysing the role of PE in APP proteolysis, membrane PE
levels were depleted by RNAi, directed against  PECT, CEPT and ETNK
enzymes that are involved in PE synthesis pathway. Inhibition of all three
enzymes led to depletion of similar amounts of membrane PE. Moreover
alterations in APP processing by its cleaving enzymes did not differ dependently
on inhibited PE synthesis enzyme. These findings indicate that changes in APP
cleavage observed in RNAi treated cells are not due to the inhibited enzyme
activity itself, but to altered PE level caused by enzyme activity inhibition.
Analysis of APP processing enzymes involved in amyloidogenic pathway show
alterations in their activity in correlation with low membrane PE levels. The
activities of ∀- and ! - secretases, read out by A!  and !CTF generation,
respectively were significantly decreased after membrane PE depletion. In
contrast, non-amyloidogenic #-secretase processing of APP, assayed by #CTF
and sAPP# levels, revealed an elevated level in low PE cells. Composition of
other membrane lipids, assayed in the membranes of RNAi treated cells,
revealed that they do not significantly differ in comparison to the non-treated
cells, so that the effect on the secretases activity seems to rely exclusively on the
changes in membrane PE levels. Furthermore an unspecific effect of RNAi itself
on APP cleavage by #-, !- and ∀-secretase was excluded by treating the cells
with RNAi directed against an irrelevant messenger RNA.
Regarding the finding above membrane PE appears to have benefit effect on the
amyloidogenic pathway of APP processing, in contrast to the non-amyloidogenic
APP processing, which is favoured in low membrane PE cells.
4.2. PE is implicated in the regulation of hAPP processing by -
secretase in Drosophila in vivo system
Results obtained in mammalian HEK 293 cells, that strongly indicate a
modulatory role of PE in APP proteolytic processing are supported by
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observations in Drosophila in vivo system. As mentioned above amyloidogenesis
depends on the interaction of ∀-, !- and #-secretase. But since APP processing
by ∀-secretase represents the crucial step in the generation of the neurotoxic A!
peptide modulation of this event appears to be most interesting for the regulation
of AD implicated amyloidogenesis.
By using Drosophila in vivo system, I could demonstrate that membrane PE
levels influence the modulation of ∀-secretase activity on APP. Like in
mammalian system, APP in Drosophila membranes colocalizes mainly with the
phospholipid rich/cholesterol poor non-raft membrane domains.
In order to address the role of membrane PE in APP cleavage by ∀-secretase, I
analysed ∀-activity in two different transgenic systems homozygous for easPC80f
mutation. Low PE flies expressing C-terminal fragment of hAPP (hAPP-Ct) were
obtained by crossing transgenic lines, carrying hAPP-Ct (GMR-APP-GAL4, UAS-
GRIM/+ and APP-GAL4-VP16, UAS-cd8-GFP/+) with low PE mutant flies
(easPC80f).
Highly conserved ∀-secretase activity in Drosophila, described by Iwatsubo and
colleagues (Takasugi et al., 2002), has been shown in previous studies to
processes hAPP in similar manner like in mammals (Fossgreen et al., 1998,
Lichtenthaler et al., 1999, Struhl and Adachi, 2000, Loewer et al., 2003, Guo et
al., 2003, Doglio et al., 2006). GMR-APP-GAL4, UAS-GRIM transgenic flies act
as a sensitive and specific reporter of the endogenous, physiological levels of ∀-
secretase (Guo et al, 2003). Also APP-GAL4-VP16, UAS-cd8-GFP is an
established model for ∀-secretase analysis (Struhl and Adachi, 2000). As easPC80
is a mutation with a known biochemical effect in phospholipid metabolism,
particularly in PE synthesis (Pavlidis et al., 1994, Nyako et al., 2001) it allows the
investigation of specific consequences of defects in phospholipids, or rather PE
metabolism.
In GMR-APP-GAL4, UAS-GRIM reporter system hAPP-Ct-GAL4 is specifically
expressed in the developing eye, in which the cell population is dominated by
neurons. ∀-secretase dependent cleavage of hAPP-Ct triggers the transcriptional
activation of a cell death activator Grim, whose expression induces retinal cell
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death. Thus, endogenous levels of ∀-secretase activity correlate with the extent of
retinal cell death, indicated by the eye size and the size of roughened eye
surface. Control reporter flies with wild-type PE level show a small and
roughened eye phenotype due to the wild-type levels of ∀-secretase activity. A
dramatic decrease of ∀-activity indicated by almost eliminated roughened eye
surface and to normal restored eye size, was obtained after reducing membrane
PE content by easPC80 mutation. An unspecific effect of easPC80 mutation on
retinal cell death was excluded in control experiments, performed in GMR-GAL4,
UAS-G/RPR/+ transgenic system. Since these transgenic flies do not express
APP and so GRIM expression is not ∀-secretase dependent, true modulators of ∀-
activity should not affect the level of retinal cell death. In fact, GMR-GAL4, UAS-
G/RPR/+ flies, homozygous for easPC80 gene show a significant decrease in
membrane PE content, but the level of retinal cell death do not differ from the
GMR-GAL4, UAS-G/RPR/+ flies with wild-type PE amount.
Results obtained by using GMR-APP-GAL4, UAS-GRIM flies were confirmed in
APP-GAL4-VP16, UAS-cd8-GFP transgenic system. In these flies endogenous ∀-
secretase activity is read out as levels of green fluorescent protein (GFP)
expression. APP-Ct-GV translocates to the nucleus after being released from the
membrane by ∀-cleavage of APP, and leads to transcriptional activation of GFP
protein, which is expressed in the whole fly. GFP expression determined by
biochemical assay and fluorescence intensity measurements appears to be
strongly decreased in transgenic flies homozygous for easPC80 mutant gene with
respect to the control flies. Decreased GFP expression in is an indicator for
downregulated ∀-activity in low PE flies, consistent to the results obtained in
GMR-APP-GAL4, UAS-GRIM reporter system.
In both systems reporter gene transcription is triggered by translocation of GV
and APP-Ct fragments, initiating downstream of the ∀-secretase cleavage site, to
the nucleus after ∀-cleavage. As A! peptide is the counterpart of this ∀-secretase
generated APP-Ct fragment, a decrease of its generation complies with a
decrease of A! peptide production.
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As mentioned above easPC80 is a mutation in ethanolamine kinase involved in PE
synthesis via CDP-ethanolamine pathway, which has been shown to be the
major source of PE in insects (Downer, 1985). Since ETNK is specifically
involved in PE synthesis, the easPC80 mutation is supposed to have no significant
effect on membrane content of other lipids. Indeed, TLC analyses of Drosophila
main membrane sterols, sphingolipids and phospholipids like ergosterol,
ceramide, PECeramide, PC and PI revealed no significant alterations in their
membrane content in easPC80 homozygous with respect to control flies. Apart of a
decrease in PE levels easPC80 mutation does not alter membrane lipid content
significantly, so that downregulated ∀-secretase activity in easPC80 homozygous
appears to rely on low membrane PE levels. Although I cannot rule out the
possibility of modulatory effect of the lipids which are not included in the analysis,
it seems unlikely that one of those lipids would affect APP regulation in a such
strong manner, considering their role in cell processes and their presence in the
membrane in comparison to the major membrane lipids, e.g. PE or ergosterol.
4.3. PE depletion leads to downregulation of -secretase in
neuronal and non-neuronal cells
Another very interesting aspect of the results obtained in GMR-APP-GAL4, UAS-
GRIM and APP-GAL4-VP16, UAS-cd8-GFP flies is that PE affects 
∀ -activity in a cell or tissue type independent manner.  In GMR-APP-GAL4, UAS-
GRIM transgenic system, ∀-activity was analysed exclusively in neuronal tissue,
whereas in APP-GAL4-VP16, UAS-cd8-GFP transgenic flies ∀-secretase activity
was assayed in whole fly, i.e. in different cell types. Given the results above PE
effect on ∀-secretase activity appears to be the same independent on cell or
tissue type. Nevertheless PE modulation of ∀-secretase in a cell type related
manner cannot be excluded. It is possible that the modulations are manifested in
more delicate manner, which was not observable in present systems.
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Although present membrane PE decrease clearly induces downregulation of ∀-
activity in neuronal and non-neuronal Drosophila cells, it may be that the
sensitive neuronal cells, different than other cell types, respond to very slight
changes in PE membrane content.
Since PE appears to be involved in ∀-secretase regulation, its membrane level
modulation may be a target for therapeutic aims. For that purpose it would be
interesting to determine the threshold of PE levels responsible for ∀-alterations in
neurons versus non-neuronal cells. Moreover this question remains to be
answered because mild changes in membrane lipid content may be important for
pathological situations. Neuronal tissue related processes, implicated in AD
pathogenesis, are likely to be influenced by slight lipid alterations, as reported in
mammalian system for the effect of moderate cholesterol loss on BACE1-activity
and A! generation (Rodriguez et al., 2004).
4.4. PE effect on -activity differs in non-differentiated,
embryonic Drosophila cells and in adult flies. Does PE correlate
with -activity depending on cell differentiation stage?
An evidence for cell type related role of PE on ∀-activity is provided by
experiments done in embryonic Drosophila S2 cells. It is important to point out
that S2 cells belong to embryonic cells, which are undifferentiated and so less
complex than the cell types assayed for ∀-activity in vivo. Different than in
Drosophila in vivo system, membrane PE depletion in S2 cells induces a strong
increase in ∀-secretase activity.
S2 cells, transiently expressing hC99, were treated with RNAi directed against
eas (ETNK) mRNA, encoded by the same gene that is mutated in easPC80 flies.
Additionally to membrane PE alterations by ethanolamine kinase (ETNK) RNAi,
S2 cells were treated with RNAi against phosphoethanolamine
cytidylyltransferase (PECT).   Inhibition of ETNK and PECT, both, enzymes
involved in PE synthesis vie CDP-ethanolamine pathway, causes PE depletion
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comparable to the one in easPC80 mutants. Like in vivo system, except of a
significant PE decrease, the content of other membrane lipids was not affected
by RNAi treatment. But other than in vivo, ∀-secretase activity, measured by A!
generation had clearly elevated levels in respect to the control cells with wild-type
PE levels. A! content in the medium shows an enormous increase after PE
depletion by RNAi treatment.
Although clearly dependent on membrane PE, alterations in levels of ∀-secretase
activity obtained in S2 cells do not correspond to those from mammalian HEK
cells and Drosophila in vivo system. This discrepancy may be due to the
embryonic, undifferentiated stage of S2 cells, that represents PE-mediated
modulation of APP in a different way than mature, differentiated cells.   This
observation raises the question, whether PE modulation of ∀-secretase activity
depends on cellular differentiation and developmental stage.
Because the mechanisms responsible for A! generation are is still poorly
understood one may speculate that pathological accumulation of A! peptide in
AD brains results from its perturbed generation at different developmental stages.
Although the answer to this question may be interesting for understanding
amyloidogenesis, the experimental approach provided by in vivo system appears
more relevant for the aim of this study, as amyloidogenesis is an event, related to
the differentiated adult cells.
4.5. Conclusion
Being an integral membrane protein APP is likely to respond to its lipid
environment. Moreover APP proteolytic processing by #- !- and ∀- secretase is a
membrane occurring event. Hence, it seems likely that membrane lipids play an
important role in the regulation of APP proteolysis. Findings presented in this
study, show that in mammalian and in Drosophila system proteolytic cleavage of
APP, which is largely restricted to the phospholipid membrane core, appears to
be modulated by these lipids, particularly by PE. Even though the observations
described here clearly indicate the PE involvement in APP proteolytic regulation,
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it is important to point out, that neither PE alone, nor the phospholipid rich phase
per se can account for full regulation of APP processing.
However, the way to understand the function of such a complex structure like cell
membrane, which is composed of thousands of lipid species, is to analyze how
individual lipids regulate activities of membrane proteins. In the present study I
analysed the modulatory role of one of the major membrane phospholipids in
APP proteolytic processing. I hypothesized that phospholipids play an important
role in APP proteolysis, relying on the fact that APP mainly accumulates in
phospholipid rich membrane core and I could establish that phospholipids,
particularly PE modulates the processing of APP in the membranes of
mammalian and Drosophila cells. As the experimental approach utilized in this
study provides information on the mean role of PE in processing of APP the
exact way by which PE regulates APP cleavage remains to be answered.
An explanation for the phospholipid modulatory role in APP proteolysis is the
separation of the cleaving machinery and the substrate into distinct membrane
microdomains. Growing evidence indicates the importance of rafts that are
enriched in active !- and ∀-secretase, as principal membrane platforms for
amyloidogenic processing of APP. As APP is mainly restricted to the non-raft
domains analysis of rafts and non-raft interaction may provide essential answers
about the regulation of APP proteolysis. It seems likely that phospholipid rich
membrane sub-domains together with lipid rafts control the access of APP to its
processing enzymes and that perturbed membrane phospholipid content disables
the access of APP to the rafts, resulting in alterations of its proteolytic cleavage.
This hypothesis is supported by findings obtained in the present study, which
show that cleavage of APP by !- and ∀-secretases, which are thought to be
enriched in lipid rafts, decrease after PE depletion. Highly elevated levels of #-
secretase products in low PE cells may be explained by the retention of APP in
phospholipid rich domains caused by altered non-rafts properties. Under these
circumstances APP accumulation in phospholipid rich membrane core would
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provide an increased substrate amount for #-secretase, which is supposed to act
in non-raft domains (Figure 4.1. A, B).
It is important to take in account that although active forms of ∀- and !-secretase
have been shown to enrich in lipid rafts, their activity is not exclusively restricted
to these domains, i.e. ∀- and !-activity on APP is present also in non-raft
domains.  Hence it is possible that ∀- and !-secretase are trafficked from rafts to
the non-rafts, to cleave APP. In this scenario altered non-rafts composition
caused by depleted membrane PE would disable !- and ∀-secretase to rich the
substratum that would result in decreased amyloidogenic APP processing in non-
raft domains (Figure 4.1. A,C), as shown in the present study. As mentioned
above a downregulation in amyloidogenic processing increases the substrate
amount for #-secretase, and consequently enhances the non-amyloidogenic
pathway.
Whether APP needs to be transported to the rafts, where active ∀- and !-
secretases enrich or the processing enzymes are trafficked to their substratum to
perform the cleavage remains to be answered. It is conceivable that these two
events exist in parallel, i.e. that both rafts and non-rafts, provide the matrix for
APP processing. However, the findings in the present study correspond to
previous work, which suggests that the key event in the regulation of APP
proteolysis is the restriction of enzyme accessibility to the substratum by
partitioning them into distinct membrane microdomains, in rafts and non-rafts. In
support to previous studies (reviewed in Kaether and Haass, 2004), which point
out the role of cholesterol in APP cleavage, here I could show that PE, a major
membrane phopsholipid, that enriches in non-raft domains clearly influences APP
proteolytic processing by #-, !-, and ∀- secretase.
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A
B
C
Figure 4.1. A model describing the effects of PE reduction on APP processing by
secretases. For details see text.
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Besides partitioning of the membrane proteins into distinct membrane
microdomains, which is described above another way to restrict their contact is to
separate them into different cellular compartments and dispatching them to
separate trafficking routes. As this may be an important way in the modulation of
APP processing by membrane lipids, the effect of membrane PE on APP in
particular membrane compartments remains to be determined.  More precise, it
remains to be answered, whether membrane PE effect on secretases differs
depending on their site of action, e.g. ∀-secretase, which has been postulated to
reside in multiple compartments including the ER, late Golgi/TGN, endosomes
and plasma membrane (Cook et al., 1997, Xu et al., 1997, Greenfiled et al.,
1999, Takahashi et al., 2002 and Kaether et al., 2002), or !-secretase that has
been reported to be the highest in late Golgi/TGN and endosomes (Koo and
Squazzo, 1994, Haass et al., 1995, Walter et al., 2001) may respond more
sensitive to membrane lipid alterations in these membrane compartments than in
the others, in which the enzyme activity is supposed to be lower.
Another possibility, how PE may contribute to the regulation of APP proteolysis
by secretases is by directly affecting the capacity of the enzyme to cleave the
substratum.  For instance, ∀-secretase enzyme complex formation may depend
on the proper organisation of phopspholipid bilayer, so that perturbations in
phospholipid rich domains caused by low membrane PE would not allow the
assembly of an active ∀-complex. Also #- and !-secretases are likely to depend
on lipidic environment that provides the matrix for their activity.
I conclude that PE appears to have a benefit effect on APP cleavage by !- and ∀-
secretases, whereas low membrane PE levels enhance the processing of APP
via non-amyloidogenic pathway. Since amyloidogenesis is a pivotal and early
event in AD pathogenesis, membrane phospholipids may be important
candidates for understanding the disease development and moreover for
developing therapeutical agents for AD treatment.
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